0000950170-23-046421 | 6-K/A | XBRL Viewer

Recognition of previously deferred upfront payments

$ 0

^[1]

$ 0

^[2]

Other revenues from collaboration agreements

^[1]

998,000

^[1]

2,530,000

^[2]

Collaboration agreements

998,000

^[1]

2,530,000

^[2]

Licenses

157,000

158,000

^[1]

264,000

276,000

^[2]

Products & services

22,000

150,000

^[1]

53,000

166,000

^[2]

Total revenues

$ 178,000

$ 1,307,000

^[3],[4]

$ 317,000

$ 2,972,000

^[5],[6]

[1]	These amounts reflect adjustments made in connection with the presentation of the discontinued operation (Note 5)
[2]	These amounts reflect adjustments made in connection with the presentation of the discontinued operation (Note 5)
[3]	These amounts reflect adjustments made in connection with the presentation of the discontinued operation (Note 5)
[4]	These amounts reflect adjustments made in connection with the presentation of the discontinued operation (Note 5)
[5]	These amounts reflect adjustments made in connection with the presentation of the discontinued operation (Note 5)
[6]	These amounts reflect adjustments made in connection with the presentation of the discontinued operation (Note 5)

The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2023-01-01
-Paragraph 28
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_a&doctype=Standard
-URIDate 2023-03-23

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2023-01-01
-Paragraph 23
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_a&doctype=Standard
-URIDate 2023-03-23

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2023-01-01
-Paragraph 32
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_32&doctype=Standard
-URIDate 2023-03-23

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 5
-IssueDate 2023-01-01
-Paragraph 33
-Subparagraph b
-Clause i
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2023-en-r&anchor=para_33_b_i&doctype=Standard
-URIDate 2023-03-23

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2023-01-01
-Paragraph 33
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_33_a&doctype=Standard
-URIDate 2023-03-23

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2023-01-01
-Paragraph 34
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_34&doctype=Standard
-URIDate 2023-03-23

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2023-01-01
-Paragraph B12
-Subparagraph b
-Clause v
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B
-URIDate 2023-03-23

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Name IFRS
-Number 12
-IssueDate 2023-01-01
-Paragraph B10
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B
-URIDate 2023-03-23

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2023-01-01
-Paragraph 82
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_a&doctype=Standard
-URIDate 2023-03-23

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Name IAS
-Number 1
-IssueDate 2023-01-01
-Paragraph 103
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_103&doctype=Standard
-URIDate 2023-03-23

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Name IAS
-Number 1
-IssueDate 2023-01-01
-Paragraph 102
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_102&doctype=Standard
-URIDate 2023-03-23

+ Details

Earnings per share (Tables)

6 Months Ended

Jun. 30, 2023

Earnings per share


	For the six-month period ended June 30,
	2022			2023
Net income (loss) attributable to shareholders of Cellectis ($ in thousands)		(50,858	)		(40,715	)
Net income (loss) attributable to shareholders of Cellectis ($ in thousands) from discontinued operations		(3,531	)		(4,984	)
Adjusted weighted average number of outstanding shares, used to calculate both basic and diluted net result per share		45,497,127			53,541,010
Basic / Diluted net income (loss) per share attributable to shareholders of Cellectis
Basic net income (loss) attributable to shareholders of Cellectis per share ($ /share)		(1.12	)		(0.76	)
Basic earnings from discontinued operations per share ($ /share)		(0.08	)		(0.09	)
Diluted net income (loss) attributable to shareholders of Cellectis per share ($ /share)		(1.12	)		(0.76	)
Diluted earnings from discontinued operations per share ( $ /share)		(0.08	)		(0.09	)

The Company	6 Months Ended
Jun. 30, 2023
Text block1 [abstract]
The Company	Note 1. The Company Cellectis S.A. (hereinafter “Cellectis” or “we”) is a limited liability company (“société anonyme”) registered and domiciled in Paris, France. We are a clinical stage biotechnological company, employing our core proprietary technologies to develop products based on gene-editing with a portfolio of allogeneic Chimeric Antigen Receptor T-cells (“UCART”) product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitors cells (“HSPC”) product candidates in other therapeutic indications. Our UCART product candidates, based on gene-edited T-cells that express Chimeric Antigen Receptors (“CARs”), seek to harness the power of the immune system to target and eradicate cancers. We believe that CAR-based immunotherapy is one of the most promising areas of cancer research, representing a new paradigm for cancer treatment. We are designing next-generation immunotherapies that are based on gene-edited CAR T-cells. Our gene-editing technologies allow us to create allogeneic CAR T-cells, meaning they are derived from healthy donors rather than the patients themselves. We believe that the allogeneic production of CAR T-cells will allow us to develop cost-effective, “off-the-shelf” products that are capable of being stored and distributed worldwide. Our gene-editing expertise also enables us to develop product candidates that feature additional safety and efficacy attributes, including control properties designed to prevent them from attacking healthy tissues, to enable them to tolerate standard oncology treatments, and to equip them to resist mechanisms that inhibit immune-system activity. Together with our focus on immuno-oncology, we are using, through our HEAL platform, our gene-editing technologies to develop HSPC product candidates in genetic diseases. Cellectis S.A., Cellectis, Inc., Cellectis Biologics, Inc. (and Calyxt, Inc. until 31 May 2023), as a consolidated group of companies, are sometimes referred to as the “Group.” On May 31, 2023, Calyxt, Inc. completed its all-stock, reverse merger business combination with Cibus Global, LLC (“Cibus Global”) (the “Merger”). Among other things, as part of the Merger, each share of Calyxt’s common stock, par value $0.0001 per share, existing and outstanding immediately prior to the Merger remained outstanding as a share of Class A common stock, par value $0.0001 per share (“Class A Common Stock”), without any conversion or exchange thereof, and Calyxt issued approximately 16,527,484 shares of Class A Common Stock to unitholders of Cibus Global based on an exchange ratio set forth in the agreement and plan of merger (the “Merger Agreement”) for the Merger. Following the closing of the Merger, effective on June 1, 2023, the combined company operates under the name of Cibus, Inc. (referred to as “Cibus”). Cellectis’ equity interest in Calyxt was reduced to 2.9% after the closing of the Merger, which resulted in Cellectis losing control of Calyxt. Calyxt is therefore no longer consolidated since June 1, 2023.

The Company

6 Months Ended

Jun. 30, 2023

Disclosure of offsetting of financial liabilities [line items]

The Company

Note 1. The Company

Cellectis S.A. (hereinafter “Cellectis” or “we”) is a limited liability company (“société anonyme”) registered and domiciled in Paris, France.

We are a clinical stage biotechnological company, employing our core proprietary technologies to develop products based on gene-editing with a portfolio of allogeneic Chimeric Antigen Receptor T-cells (“UCART”) product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitors cells (“HSPC”) product candidates in other therapeutic indications.

Our UCART product candidates, based on gene-edited T-cells that express Chimeric Antigen Receptors (“CARs”), seek to harness the power of the immune system to target and eradicate cancers. We believe that CAR-based immunotherapy is one of the most promising areas of cancer research, representing a new paradigm for cancer treatment. We are designing next-generation immunotherapies that are based on gene-edited CAR T-cells. Our gene-editing technologies allow us to create allogeneic CAR T-cells, meaning they are derived from healthy donors rather than the patients themselves. We believe that the allogeneic production of CAR T-cells will allow us to develop cost-effective, “off-the-shelf” products that are capable of being stored and distributed worldwide. Our gene-editing expertise also enables us to develop product candidates that feature additional safety and efficacy attributes, including control properties designed to prevent them from attacking healthy tissues, to enable them to tolerate standard oncology treatments, and to equip them to resist mechanisms that inhibit immune-system activity.

Together with our focus on immuno-oncology, we are using, through our HEAL platform, our gene-editing technologies to develop HSPC product candidates in genetic diseases.

Cellectis S.A., Cellectis, Inc., Cellectis Biologics, Inc. (and Calyxt, Inc. until 31 May 2023), as a consolidated group of companies, are sometimes referred to as the “Group.”

On May 31, 2023, Calyxt, Inc. completed its all-stock, reverse merger business combination with Cibus Global, LLC (“Cibus Global”) (the “Merger”). Among other things, as part of the Merger, each share of Calyxt’s common stock, par value $0.0001 per share, existing and outstanding immediately prior to the Merger remained outstanding as a share of Class A common stock, par value $0.0001 per share (“Class A Common Stock”), without any conversion or exchange thereof, and Calyxt issued approximately 16,527,484 shares of Class A Common Stock to unitholders of Cibus Global based on an exchange ratio set forth in the agreement and plan of merger (the “Merger Agreement”) for the Merger. Following the closing of the Merger, effective on June 1, 2023, the combined company operates under the name of Cibus, Inc. (referred to as “Cibus”). Cellectis’ equity interest in Calyxt was reduced to 2.9% after the closing of the Merger, which resulted in Cellectis losing control of Calyxt. Calyxt is therefore no longer consolidated since June 1, 2023.

Deferred Revenues and Contract Liabilities - Summary of Deferred Revenues and Contract Liabilities (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Accruals and deferred income including contract liabilities [abstract]
Deferred revenues and contract liabilities	$ 241	$ 59
Total Deferred revenue and contract liabilities	$ 241	$ 59

Financial Liabilities - Schedule of Sensitivity Of The Fair Value To The Expected Volatility (Detail) - Tranche A Warrants [Member] - USD ($) $ in Thousands	Jun. 30, 2023	Apr. 17, 2023
Disclosure of financial liabilities [line items]
Expected volatility -5%	$ 4,790	$ 5,206
Expected volatility	4,875	5,224
Expected volatility +5%	$ 4,925	$ 5,231

Financial Liabilities - Schedule of Assumptions of Warrants Valuation (Detail) - Tranche A Warrants [Member]

6 Months Ended

Jun. 30, 2023

€ / shares

Grant Date

Apr. 17, 2023

^[1]

Expiration Date

Apr. 17, 2043

Number of options granted

2,779,188

Share entitlement per option

Exercise price (in euros per option) | € / shares

€ 1.92

Valuation method

Longstaff Schwartz

[1]	The grant date retained is the disbursement date of the Tranche A as this is the issuance date defined in the contract.

Non-cash stock-based compensation - Summary of Information on Warrants Activity (Detail) - Non Employee Warrants [Member]	6 Months Ended	12 Months Ended
	Jun. 30, 2023 € / shares	Dec. 31, 2022 € / shares	Dec. 31, 2021 € / shares
Disclosure Of Number And Weighted Average Exercise Prices Of Share Options and awards [Line Items]
Option exercisable, beginning balance	896,225	896,225
Option exercisable, ending balance	896,225	896,225	896,225
Weighted- average exercise price per share, beginning balance	€ 27.18	€ 27.18
Weighted- average exercise price per share, ending balance	€ 27.18	€ 27.18	€ 27.18
Option outstanding, beginning balance	896,225	896,225
Option outstanding, ending balance	896,225	896,225	896,225
Weighted average exercise price per share, beginning balance	€ 27.18	€ 27.18
Weighted average exercise price per share, ending balance	€ 27.18	€ 27.18	€ 27.18
Remaining Average Useful Life	2 years 9 months 18 days	3 years 3 months 18 days	4 years 3 months 18 days

Right-of-use assets

6 Months Ended

Jun. 30, 2023

Right-of-use assets

Note 7. Right-of-use assets

Details of Right-of-use assets

Under the provision of IFRS 16 “Leases”, the Company recognizes a right of use asset and lease liability on the Statement of financial position.

The breakdown of right-of-use assets is as follows:


	Building lease			Office and laboratory equipment			Total
	$ in thousands
Net book value as of January 1, 2022		55,197			14,226			69,423
Additions		487			328			816
Depreciation expense		(1,418	)		(1,225	)		(2,642	)
Translation adjustments		(304	)		(64	)		(369	)
Net book value as of June 30, 2022		53,962			13,265			67,227
Gross value at end of period		69,847			19,875			89,721
Accumulated depreciation and impairment at end of period		(15,885	)		(6,609	)		(22,494	)
Net book value as of January 1, 2023		33,666			10,608			44,275
Additions		879			96			975
Disposal of right-of-use asset		(102	)		—			(102	)
Depreciation expense		(2,292	)		(1,685	)		(3,977	)
Translation adjustments		237			49			286
Net book value as of June 30, 2023		32,389			9,068			41,457
Gross value at end of period		50,684			17,932			68,616
Accumulated depreciation at end of period		(18,295	)		(8,864	)		(27,159	)

Non-current Financial Assets - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Disclosure of detailed information about property, plant and equipment [line items]
Diminution related to supplier deposit reimbursement	$ 400
Non current restricted cash	4,656	$ 4,716
Investments in non consolidated entities	5,032	$ 0
Raleigh, North Carolina [Member] \| Leased Equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Non current restricted cash	1,900
Raleigh, North Carolina [Member] \| Leased Premises [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Non current restricted cash	2,600
New York [Member] \| Leased Premises [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Non current restricted cash	200
Cibus, Inc. [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Investments in non consolidated entities	$ 5,000
Closing stock price	$ 10.5

Current Financial Assets and Cash and Cash Equivalents - Additional Information (Detail) - USD ($) $ in Thousands		1 Months Ended	4 Months Ended	6 Months Ended
	Dec. 22, 2022	Apr. 30, 2022	Dec. 31, 2021	Jun. 30, 2023	Apr. 30, 2023	Dec. 31, 2022
Disclosure of current financial assets and cash and cash equivalents [line items]
Short term restricted cash				$ 0		$ 0
Current trade receivables				422		772
Current financial assets				1,120		7,907
Cytovia Agreement [Member]
Disclosure of current financial assets and cash and cash equivalents [line items]
Other current financial assets				1,100		7,900
Cytovia Agreement [Member] \| Accrued and unpaid interest accrued [Member]
Disclosure of current financial assets and cash and cash equivalents [line items]
Amount of convertible note due and payable in full cash				2,400
Cytovia Agreement [Member] \| Principal [Member]
Disclosure of current financial assets and cash and cash equivalents [line items]
Amount of convertible note due and payable in full cash				$ 20,000
Cytovia Agreement [Member] \| Cytovia [Member]
Disclosure of current financial assets and cash and cash equivalents [line items]
Step up interest rate percentage on notes receivable				10.00%
Current financial assets				$ 1,100
Impact of derecognition of the initial asset				(7,900)
Impact of recognition of new asset				1,100
Net profit or loss in fair value of assets				(6,800)
Cytovia Agreement [Member] \| Cytovia [Member] \| Convertible Notes [Member]
Disclosure of current financial assets and cash and cash equivalents [line items]
Amount of convertible note due and payable in full cash				$ 22,400
Cellectis [Member] \| Cytovia Agreement [Member]
Disclosure of current financial assets and cash and cash equivalents [line items]
Conversion of notes receivable into trade receivables			$ 20,000
Calyxt [Member]
Disclosure of current financial assets and cash and cash equivalents [line items]
Restricted cash						$ 200
Debt securities [member] \| Cellectis [Member] \| Cytovia Agreement [Member] \| Amendment Agreement One [Member]
Disclosure of current financial assets and cash and cash equivalents [line items]
Convertible note nominal amount		$ 20,000
Debt securities [member] \| Cellectis [Member] \| Cytovia Agreement [Member] \| Amended And Restated Agreement [Member] \| Cytovia [Member] \| Amendment Agreement One [Member]
Disclosure of current financial assets and cash and cash equivalents [line items]
Minimum threshold percentage of ownership necessary for conversion of notes receivable into shares	9.90%
Notes receivable rate of interest	10.00%
Step up interest rate percentage on notes receivable	10.00%
Debt securities [member] \| Cellectis [Member] \| Cytovia Agreement [Member] \| Due On June 30, 2023 [Member] \| Amended And Restated Agreement [Member] \| Cytovia [Member] \| Amendment Agreement One [Member]
Disclosure of current financial assets and cash and cash equivalents [line items]
Percentage of notes receivable due to be received	50.00%
Percentage of convertible notes due at final maturity					100.00%
Debt securities [member] \| Cellectis [Member] \| Cytovia Agreement [Member] \| Due On April 30, 2023 [Member] \| Amended And Restated Agreement [Member] \| Cytovia [Member] \| Amendment Agreement One [Member]
Disclosure of current financial assets and cash and cash equivalents [line items]
Percentage of notes receivable due to be received	50.00%

Deferred Revenues and Contract Liabilities - Additional Information (Detail) $ in Millions	6 Months Ended
	Jun. 30, 2023 USD ($)
Accruals and deferred income including contract liabilities [abstract]
Increase in deferred revenues and contract liabilities	$ 0.2

Provisions - Additional Information (Detail) $ in Millions	6 Months Ended
Provisions - Additional Information (Detail) $ in Millions	Jun. 30, 2023 USD ($)
Commercial litigation [member]
Disclosure of provisions [line items]
Provisions for termination benefits	$ 0.5

Impairment tests

6 Months Ended

Jun. 30, 2023

Impairment tests

Note 6. Impairment tests

Accounting policy

Amortizable intangible assets, depreciable tangible assets and right-of-use are tested for impairment when there is an indicator of impairment. Impairment tests involve comparing the carrying amount of cash-generating units with their recoverable amount. The recoverable amount of an asset is the higher of (i) its fair value less costs to sell and (ii) its value in

use. If the recoverable amount of any asset is below its carrying amount, an impairment loss is recognized to reduce the carrying amount to the recoverable amount.

Our cash-generating units (“CGUs”) correspond to the operating/reportable segments: Therapeutics and Plants. Plants’ CGU is classified as held for sale until May 31, 2023.

Results of impairment test

No indicator of impairment has been identified for any intangible or tangible assets in either of the CGUs for the six months periods ended June 30, 2022 or 2023.

The CGU corresponding to the Plants segment consisted solely of Calyxt. Since the deconsolidation of Calyxt on June 1, 2023, our retained investment in Calyxt is measured at fair value, based on Cibus share price on the Nasdaq.

As from June 1, 2023, there is a single CGU corresponding to the Plants segment.

Cover Page	6 Months Ended
Cover Page	Jun. 30, 2023
Document Information [Line Items]
Document Type	6-K/A
Amendment Flag	false
Document Period End Date	Jun. 30, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q2
Entity Registrant Name	Cellectis S.A.
Entity Central Index Key	0001627281
Current Fiscal Year End Date	--12-31
Entity File Number	001-36891

Trade receivables and other current assets (Tables)

6 Months Ended

Jun. 30, 2023

Disclosure of Trade Receivables

10.1 Trade receivables


	As of December 31,		As of June 30,
	2022		2023
	$ in thousands
Trade receivables		772		422
Total net value of trade receivables		772		422

Disclosure of Subsidies Receivables

10.2 Subsidies receivables


	As of December 31,		As of June 30,
	2022		2023
	$ in thousands
Research tax credit		14,496		19,180
Other subsidies		—		308
Total subsidies receivables		14,496		19,488

Disclosure of Other Current Assets

10.3 Other current assets


	As of December 31,		As of June 30,
	2022		2023
	$ in thousands
VAT receivables		1,140		999
Prepaid expenses and other prepayments		6,233		5,979
Tax and social receivables		1,166		63
Deferred expenses and other current assets		538		828
Total other current assets		9,078		7,869

Financial Assets and Liabilities - Additional Information (Detail) $ in Thousands, € in Millions	Jun. 30, 2023 EUR (€)	Jun. 30, 2023 USD ($)	Dec. 31, 2022 USD ($)	Feb. 28, 2022 USD ($)
Disclosure of financial assets and liabilities [line items]
Cash and cash equivalents		$ 84,386	$ 89,789
Borrowings		40,270	20,531
State Guaranteed Loan, value		20,100
Non current financial assets		13,006	$ 8,791
FRANCE
Disclosure of financial assets and liabilities [line items]
Research tax credit receivable		$ 3,400		$ 800
State Guaranteed Loan [Member]
Disclosure of financial assets and liabilities [line items]
State Guaranteed Loan, value \| €	€ 18.5

Share capital and premium related to the share capitals (Tables)

6 Months Ended

Jun. 30, 2023

Schedule of Classes of Share Capital


Nature of the Transactions	Share Capital		Share premium			Number of shares		Nominal value
	$ in thousands (except number of shares)							in $
Balance as of January 1, 2022		2,945		934,696			45,484,310	0.05
Exercise of share warrants, employee warrants and stock options		1		—			26,500		—
Non-cash stock-based compensation expense		—		5,331			—		—
Other movements		—		(372,744	)		—		—
Balance as of June 30, 2022		2,946		567,284			45,510,810	0.05
Balance as of January 1, 2023		2,955		583,122			45,675,968	0.05
Non-cash stock-based compensation expense		—		4,053			—		—
Capital increase of Cellectis (1)		536		24,482			9,907,800
Transaction costs related to Cellectis’ capital increase (2)		—		(1,455	)		—		—
Other movements		—		(133,976	)		—		—
Balance as of June 30, 2023		3,491		476,224			55,583,768	0.05

Non-current Financial Assets (Tables)

6 Months Ended

Jun. 30, 2023

Summary of Non-current Financial Assets


	As of December 31,		As of June 30,
	2022		2023
	$ in thousands
Deposit		1,216		800
Non current restricted cash		4,716		4,656
Investments in non consolidated entities		—		5,032
Other non current financial assets		2,859		2,518
Non current financial assets		8,791		13,006

Provisions (Tables)

6 Months Ended

Jun. 30, 2023

Details of Provisions


	December 31, 2022		Additions		Amounts used during the period		Reversals		OCI		June 30, 2023
	$ in thousands
Pension		2,390		163		—		—		88		2,641
Employee litigation and severance		234		50		—		—		4		288
Commercial litigation		243		491		—		—		7		741
Total		2,867		704		—		—		100		3,671
Non-current provisions		2,390		163		—		—		88		2,641
Current provisions		477		541		—		—		11		1,029

Deferred revenues and contract liabilities (Tables)

6 Months Ended

Jun. 30, 2023

Details of Deferred Revenues and Contract Liabilities


	As of December 31, 2022		As of June 30, 2023
	$ in thousands
Deferred revenues and contract liabilities		59		241
Total Deferred revenue and contract liabilities		59		241

Current Financial Assets and Cash and Cash Equivalents - Schedule of Fair Value Through Profit and Loss (Details) - Cytovia Agreement [Member] - Cytovia [Member] $ in Thousands	Jun. 30, 2023 USD ($)
Disclosure of current financial assets and cash and cash equivalents [line items]
Expected occurrence of most probable scenario +20%	$ 224
Expected occurrence of most probable scenario	1,120
Expected occurrence of most probable scenario -20%	$ 2,015

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands

3 Months Ended

6 Months Ended

Jun. 30, 2023

Jun. 30, 2022

^[2]

Jun. 30, 2023

Jun. 30, 2022

Profit or loss [abstract]

Revenues

$ 178

$ 1,307

^[1]

$ 317

$ 2,972

^[3],[4]

Other income

1,823

1,416

^[1]

5,242

3,551

^[3],[4]

2,001

2,723

^[1]

5,560

6,523

^[3],[4]

Operating expenses

(55)

(329)

^[5]

(389)

(714)

^[4],[6]

(22,144)

(25,630)

(43,225)

(52,231)

^[4]

Other operating income (expenses)

(3,950)

(4,830)

(8,914)

(10,893)

^[4]

490

753

^[5]

(83)

774

^[4],[6]

(25,660)

(30,036)

(52,612)

(63,064)

^[4]

Net Financial gain (loss)

(23,659)

(27,313)

(47,053)

(56,541)

^[4]

Financial income

32,266

9,992

33,041

12,263

^[4]

Financial expenses

(16,284)

(1,691)

(21,461)

(3,050)

^[4]

15,982

8,301

11,580

9,213

^[4]

Income (loss) from continuing operations

258

(258)

^[4]

(7,935)

(19,012)

(35,731)

(47,328)

^[4]

Income (loss) from discontinued operations

(5,647)

(442)

(10,377)

(6,883)

^[4]

Attributable to shareholders of Cellectis

(13,583)

(19,454)

(46,108)

(54,211)

^[4],[7]

(10,648)

(18,946)

(40,715)

(50,858)

^[4]

Attributable to non-controlling interests

$ (2,935)

$ (506)

$ (5,393)

$ (3,352)

^[4]

Basic / Diluted net income (loss) per share attributable to shareholders of Cellectis

Basic net income (loss) attributable to shareholders of Cellectis per share ($ /share)

$ (0.19)

$ (0.42)

$ (0.76)

$ (1.12)

^[4]

Diluted net income (loss) attributable to shareholders of Cellectis per share ($ /share)

(0.19)

(0.42)

(0.76)

(1.12)

^[4]

Basic net income (loss) attributable to shareholders of Cellectis per share ($ /share) from discontinued operations

(0.05)

(0.09)

(0.08)

^[4]

Diluted net income (loss) attributable to shareholders of Cellectis per share ($ /share) from discontinued operations

$ (0.05)

$ 0

$ (0.09)

$ (0.08)

^[4]

Number of shares used for computing

Basic

53,541,010

45,497,127

[1]	These amounts reflect adjustments made in connection with the presentation of the discontinued operation (Note 5)
[2]	These amounts reflect adjustments made in connection with the presentation of the discontinued operation (Note 5)
[3]	These amounts reflect adjustments made in connection with the presentation of the discontinued operation (Note 5)
[4]	These amounts reflect adjustments made in connection with the presentation of the discontinued operation (Note 5)
[5]	These amounts reflect adjustments made in connection with the presentation of the discontinued operation (Note 5)
[6]	These amounts reflect adjustments made in connection with the presentation of the discontinued operation (Note 5)
[7]	These amounts reflect adjustments made in connection with the presentation of the discontinued operation (Note 5)

Accounting principles (Policies)	6 Months Ended
Accounting principles (Policies)	Jun. 30, 2023
Text block1 [abstract]
Basis for preparation	2.1 Basis for preparation The Interim Consolidated Financial Statements of Cellectis as of, and for the six-month period ended, June 30, 2023 were approved by our Board of Directors on August 3, 2023. The Interim Consolidated Financial Statements are presented in thousands of U.S. dollars. See Note 2.2. The Interim Consolidated Financial Statements as of, and for the six-month period ended June 30, 2023 have been prepared in accordance with International Accounting Standard (“IAS”) 34 Interim Financial Reporting, as issued by the International Accounting Standards Board (“IASB”). The Interim Consolidated Financial Statements as of and for the six-month period ended June 30, 2023 have been prepared using the same accounting policies and methods as those applied for the year ended December 31, 2022, except as described below related to the new or amended accounting standards applied. IFRS include International Financial Reporting Standards (“IFRS”), International Accounting Standards (“the IAS”), as well as the interpretations issued by the Standards Interpretation Committee (“the SIC”), and the International Financial Reporting Interpretations Committee (“IFRIC”). Application of new or amended accounting standards or new amendments The following pronouncements and related amendments have been adopted by us from January 1, 2023 but had no significant impact on the Interim Consolidated Financial Statements: • IFRS 17 Insurance Contracts (including Amendments to IFRS 17 issued in June 2020 and Amendment to IFRS 17 - Initial Application of IFRS 17 and IFRS 9 – Comparative Information issued in December 2021) (issued in May 2017 and Effective for the accounting periods as of January 1, 2023) • Amendments to IAS 1 – Classification of Liabilities as Current or Non-current (issued in July 2020 and Effective for the accounting periods as of January 1, 2023) • Amendments to IAS 8 – Definition of Accounting Estimates (issued on 12 February 2021 and Effective for the accounting periods as of January 1, 2023) • Amendments to IAS 1 and IFRS Practice Statement 2 –Disclosure of Accounting Policies (issued in March 2021 and Effective for the accounting periods as of January 1, 2023) • Amendments to IAS 12 – Income Taxes: Deferred Tax related to Assets and Liabilities arising from a Single Transaction (issued in May 2021 and Effective for the accounting periods as of January 1, 2023) Accounting standards, interpretations and amendments issued but not yet effective The following pronouncements and related amendments are applicable for first quarter accounting periods beginning after January 1, 2024, or later, as specified below. The Group has not early adopted any of these pronouncements and amendments. We are currently evaluating if the adoption of these pronouncements and amendments will have a material impact on our results of operations, financial position, or cash flows: • Amendments to IAS 1 regarding the classification of liabilities (issued in January 2020 and Effective for the accounting periods as of January 1, 2024) • Amendments to IAS 1 regarding the classification of debt with covenants (issued in October 2022 and Effective for the accounting periods as of January 1, 2024) • Amendment to IFRS 16 to “clarify how a seller-lessee subsequently measures sale and leaseback transactions” (issued in September 2022 and Effective for the accounting periods as of January 1, 2024) Going concern The consolidated financial statements were prepared on a going concern basis. With cash and cash equivalents of $84,386 thousand as of June 30, 2023, the Company believes it has sufficient resources to continue operating for at least twelve months following the consolidated financial statements’ publication. Our assessment of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves uncertainties, and actual results could vary as a result of a number of factors. We have based this estimate on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect or chose to revise our strategy to extend our cash runway. To the extend that the company has built its cash forecast to support its ability to continue as a going concern, management considers to have the ability to extend the cash runway even further by prioritizing some clinical programs, save SG&A expenses, raising funds on the markets.
Currency of the financial statements	2.2 Currency of the financial statements The Interim Consolidated Financial Statements are presented in U.S. dollars, which differs from the functional currency of Cellectis, which is the euro. We believe that this presentation enhances the comparability with peers, which primarily present their financial statements in U.S. dollars. All financial information (unless indicated otherwise) is presented in thousands of U.S. dollars. The statements of financial position of consolidated entities having a functional currency different from the U.S. dollar are translated into U.S. dollars at the closing exchange rate (spot exchange rate at the statement of financial position date) and the statements of operations, statements of comprehensive income (loss) and statements of cash flows of such consolidated entities are translated at the average period to date exchange rate. The resulting translation adjustments are included in equity under the caption “Accumulated other comprehensive income (loss)” in the Statements of Changes in Shareholders’ Equity.
Consolidated entities and non-controlling interests	2.3 Consolidated entities and non-controlling interests Accounting policy We control all the legal entities included in the consolidation. An investor controls an investee when the investor is exposed to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee. Control requires power, exposure to variability of returns and a linkage between the two. To have power, the investor needs to have existing rights that give it the current ability to direct the relevant activities that significantly affect the investee’s returns. In order to ascertain control, potential voting rights which are substantial are taken into consideration. Consolidation of a subsidiary begins when the Group obtains control over the subsidiary and ceases when the Group loses control of the subsidiary. All intra-Group assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated in full in the consolidation. Investments in associates Associates are entities in which the Group has significant influence in respect of financial and operating policy decisions, but not control. Significant influence is assessed through voting rights. Investments in associates are accounted for under the equity method and are initially recognized at cost. The consolidated financial statements include the Group’s share of the total comprehensive income of associates from the date when significant influence is obtained until the date it ceases. If the Group’s share of losses exceeds its equity interest, the carrying amount of investments consolidated under the equity method is reduced to zero and the Group ceases to recognize its share of future losses unless the Group has a legal or constructive obligation to bear a portion of future losses or to make payments on behalf of the associate.

Non-current Financial Assets - Summary of Non-current Financial Assets (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Categories of non-current financial assets [abstract]
Deposit	$ 800	$ 1,216
Non current restricted cash	4,656	4,716
Investments in non consolidated entities	5,032	0
Other non current financial assets	2,518	2,859
Non current financial assets	$ 13,006	$ 8,791

Trade Receivables and Other Current Assets - Additional Information (Detail) $ in Thousands, € in Millions	6 Months Ended
	Jun. 30, 2023 EUR (€)	Jun. 30, 2023 USD ($)	Mar. 08, 2023 EUR (€)	Dec. 31, 2022 USD ($)	Feb. 28, 2022 USD ($)
Prepaid expenses and other current assets [line items]
Trade receivables		$ 422		$ 772
Deferred expenses and other current assets		828		$ 538
UpfrontAmount \| €	€ 1.0
Other revenues recognized		300
key Step Payment \| €	€ 1.9
Increase in deferred expenses and other current assets		300
Trade receivables related to American depositary receipts program		400
Grant and refundable advance agreement [Member]
Prepaid expenses and other current assets [line items]
Grant and refundable advance agreement \| €			€ 6.4
Percentage of grant agreement			14.77%
Percentage of refundable advance agreement			85.23%
License Agreement with One Partner [Member]
Prepaid expenses and other current assets [line items]
Trade receivables		200
Cellectis [member]
Prepaid expenses and other current assets [line items]
Payment of receivable related to extension of option term		500
France [member]
Prepaid expenses and other current assets [line items]
Research tax credit receivables		3,400			$ 800
France [member] \| Previously stated [member]
Prepaid expenses and other current assets [line items]
Research tax credit receivables		$ 15,800

Unaudited Condensed Consolidated Statements of Changes in Shareholders' Equity - USD ($)
$ in Thousands

Total

Cellectis SA [Member]

^[4]

Calyxt Inc [member]

Share Capital Ordinary Shares [member]

Premiums Related to Share Capital [member]

Cellectis SA [Member]

^[4]

Currency Translation Adjustment [member]

Calyxt Inc [member]

Retained Earnings (Deficit) [member]

Calyxt Inc [member]

Income (Loss) [member]

Attributable to Shareholders of Cellectis [member]

Cellectis SA [Member]

^[4]

Attributable to Shareholders of Cellectis [member]

Calyxt Inc [member]

Non controlling Interests [member]

Calyxt Inc [member]

Beginning balance at Dec. 31, 2021

$ 236,474

$ 2,945

$ 934,696

$ (18,021)

$ (584,129)

$ (114,197)

$ 221,293

$ 15,181

Beginning balance, shares at Dec. 31, 2021

45,484,310

Other comprehensive income (loss)

Net Loss

(54,211)

^[1],[2]

(50,858)

(3,352)

(10,760)

(11,605)

1,218

(10,387)

(373)

Total Comprehensive income (loss)

(64,971)

^[1]

(11,605)

1,218

(50,858)

(61,246)

(3,725)

Allocation of prior period loss

(114,197)

114,197

Issuance of Calyxt's common stock and exercise of Calyxt's pre-funded warrants

$ 2,733

$ 1,402

$ 1,331

Transaction with subsidiaries

2,152

(2,152)

Exercise of share warrants and employee warrants, amount

$ 1

(1)

Exercise of share warrants and employee warrants, shares

26,500

Non-cash stock-based compensation expense

6,285

5,331

954

Balance at end of year at Jun. 30, 2022

(372,744)

372,744

180,522

$ 2,946

567,284

(29,626)

(320,812)

(50,858)

168,933

11,588

Ending balance, shares at Jun. 30, 2022

45,510,810

Beginning balance at Dec. 31, 2022

125,941

$ 2,955

583,122

(28,605)

(333,365)

(106,139)

117,968

7,973

Beginning balance, shares at Dec. 31, 2022

45,675,968

Other comprehensive income (loss)

Net Loss

(46,108)

(40,715)

(5,393)

997

(415)

(42)

(458)

1,454

Total Comprehensive income (loss)

(45,111)

(415)

(42)

(40,715)

(41,172)

(3,939)

Allocation of prior period loss

(106,139)

106,139

Capital Increase

^[3]

25,017

$ 536

24,482

25,017

Capital Increase, Shares

^[3]

9,907,800

Transaction costs

$ (1,455)

(1,455)

$ 1,455

Operation between shareholders

^[5]

342

(342)

Loss of control over

^[6]

(4,440)

$ (4,440)

OCI Reclassification pursuant to Calyxt's deconsolidation

^[7]

$ (8,042)

$ (8,030)

$ (12)

$ (8,042)

Non-cash stock-based compensation expense

4,905

4,053

852

Balance at end of year at Jun. 30, 2023

^[8]

(257)

(133,976)

133,824

(152)

(105)

$ 96,558

$ 3,491

$ 476,224

$ (37,050)

$ (305,392)

$ (40,715)

$ 96,558

$ 0

Ending balance, shares at Jun. 30, 2023

55,583,768

[1]	These amounts reflect adjustments made in connection with the presentation of the discontinued operation (Note 5)
[2]	These amounts reflect adjustments made in connection with the presentation of the discontinued operation (Note 5)
[3]	During the six-month period ended June 30, 2023, 9,907,800 shares were issued in a February 2023 follow-on offering of American Depositary Shares (ADSs) with gross proceeds of $24.8 million (the Cellectis Follow-on Offering).
[4]	These costs correspond to the issuance costs incurred in 2023 in connection with the Cellectis Follow-on Offering as a reduction of share premium, in addition to the $0.6 million costs incurred and deducted from Equity in the fourth quarter of 2022. The total transaction costs for this Cellectis Follow-on Offering amount to $2.0 million.
[5]	Operations between shareholders during the six months period ended June 30, 2023 correspond to the reduction in Cellectis’ percentage of interest in Calyxt from 49.1% at December 31, 2022 to 48.0% at May 31, 2023, without change in the consolidation method until May 31, 2023.
[6]	On May 31, 2023, Calyxt consummated the Merger (as defined below) with Cibus Global. As from the consummation of the Merger, Cellectis has lost control over Calyxt and we proceeded with its deconsolidation. The net impact on Total Shareholders’ Equity corresponds to the derecognition of minority interests in Calyxt for $4.4 million.
[7]	We have reclassified at the date of loss of control amounts previously recognized in other comprehensive income related to Calyxt that should be reclassified in profit or loss according to IFRS 10.
[8]	During the annual shareholders meeting of June 27, 2023, the shareholders, in accordance with French Law, approved the absorption of $134.0 million of retained earnings into share premium. This transaction has no impact on the total equity, comprehensive income (loss), assets (including cash) nor liabilities.

Non-current Financial Assets

6 Months Ended

Jun. 30, 2023

Non-current Financial Assets

Note 9. Non-current financial assets


	As of December 31,		As of June 30,
	2022		2023
	$ in thousands
Deposit		1,216		800
Non current restricted cash		4,716		4,656
Investments in non consolidated entities		—		5,032
Other non current financial assets		2,859		2,518
Non current financial assets		8,791		13,006

As of June 30, 2023, our deposits consist of one deposit for our leased premises in Paris. The diminution of $0.4 million since December 31, 2022 is related to a supplier deposit reimbursement.

As of June 30, 2023, our non-current restricted cash primarily consists of $1.9 million related to a leasing agreement for equipment in Raleigh, $2.6 million for our leased premises in Raleigh and $0.2 million for our leased premises in New-York.

As of June 30, 2023, our non-current financial assets relate to the partial sublease of our premises in New York which started in June 2022.

Pursuant to Calyxt deconsolidation, our investment in Calyxt was classified as a non-current financial asset and measured at fair value as of June 30, 2023 for $5.0 million. The Cibus shares held by Cellectis remain listed on the Nasdaq Capital Market under the ticker symbol “CBUS” and were measured using the closing stock price of $10.50 on June 30, 2023

Discontinued Operations - Additional Information (Detail) - shares	May 31, 2023	Apr. 24, 2023	Jun. 30, 2023	Jun. 01, 2023	Dec. 31, 2022	Jun. 30, 2022	Dec. 31, 2021
Schedule Of Income Statement Of Discontinued Operations [Line Items]
Number of shares outstanding			55,583,768		45,675,968	45,510,810	45,484,310
Calyxt [member]
Schedule Of Income Statement Of Discontinued Operations [Line Items]
Percentage of voting equity interests acquired	48.00%
Number of shares outstanding	997,745
Stockholders equity, reverse stock split	1-for-5	1-for-10
Cibus, Inc. [Member]
Schedule Of Income Statement Of Discontinued Operations [Line Items]
Percentage of voting equity interests acquired				2.90%
Cellectis S.A. [Member] \| Calyxt [member]
Schedule Of Income Statement Of Discontinued Operations [Line Items]
Number of shares outstanding	479,264
Class A Common Stock [Member] \| Calyxt [member]
Schedule Of Income Statement Of Discontinued Operations [Line Items]
Number of shares issued	16,527,484
Class A Common Stock [Member] \| Cibus Global [Member]
Schedule Of Income Statement Of Discontinued Operations [Line Items]
Number of shares issued	16,527,484

Commitments

6 Months Ended

Jun. 30, 2023

Schedule Of Income Statement Of Discontinued Operations [Line Items]

Commitments

Note 19. Commitments


As of June 30, 2023	Total		Less than 1 year		1 - 3 years		3 - 5 years		More than 5 years
	$ in thousands
License and collaboration agreements		14,605		1,450		2,900		2,900		7,355
Clinical & Research and Development agreements		70		70		—		—		—
IT licensing agreements		525		525		—		—		—
Total commitments		15,200		2,045		2,900		2,900		7,355

Obligations under the terms of license and collaboration agreements

We have entered into various license agreements with third parties that subject us to certain fixed license fees, as well as fees based on future events, such as research and sales milestones. We also have collaboration agreements whereby we are obligated to pay royalties and milestone payments based on future events that are uncertain and therefore they are not included in the table above.

Obligations under the terms of Clinical & Research agreements

We have entered into clinical and research agreements where we are obligated to pay for services to be provided regarding our research collaboration agreements, clinical trials and translational research projects.

Obligations under the terms of IT licensing agreements

We have entered into an IT licensing agreement and have related obligations to pay licensing fees.

Discontinued operations (Tables)

6 Months Ended

Jun. 30, 2023

Schedule Of Income Statement Of Discontinued Operations

The results of Calyxt are as follows :


	For the six-month period ended June 30,
	2022			2023 **
Revenues and other income		73			43
Operating expenses		(12,856	)		(7,113	)
Operating income (loss)		(12,783	)		(7,070	)
Net Financial gain (loss)		5,900			(3,307	)
Net income (loss) from discontinued operations		(6,883	)		(10,377	)

** Figures for the six-month period ended June 30, 2023 include Calyxt’s results over a five-month period from January 1, 2023 to May 31, 2023

The earning per share attributable to Calyxt is as follows :


	For the six-month period ended June 30,
	2022			2023 **
Basic net income (loss) attributable to shareholders of Cellectis per share ($ /share) from discontinued operations		(0.08	)		(0.09	)
Diluted net income (loss) attributable to shareholders of Cellectis per share ($ /share) from discontinued operations		(0.08	)		(0.09	)

** Figures for the six-month period ended June 30, 2023 include Calyxt’s results over a five-month period from January 1, 2023 to May 31, 2023

Schedule Of Income Statement Of Discontinued Operations [Line Items]

Disclosure Of Detailed Information About Assets And Liabilities Held For Sale Discontinued Operations Explanatory

The major classes of assets and liabilities of Calyxt classified as held for sale are as follows:


	As of December 31,		As of May 31,			As of June 30,
	2022		2023 **			2023
Intangible assets		697		697			—
Property, plant, and equipment		4,110		4,118			—
Right-of-use assets		13,263		13,139			—
Other non-current assets		—		—			—
Other current assets		272		119			—
Cash and cash equivalents		3,427		1,642			—
Total assets held for sale		21,768		19,714			—
Non-current lease debts		13,387		13,140			—
Other non-current liabilities		—		—			—
Current financial liabilities		267		5,647			—
Current lease debts		463		406			—
Trade payables		747		2,567			—
Other current liabilities		—		220			—
Total liabilities related to assets held for sale		14,864		21,980			—
Net assets held for sale		6,903		(2,266	)		—

Schedule Of Cash Flow Statement Of Discontinued Operations

The net cash flows attributable to Calyxt are as follows:


	For the six-month period ended June 30,
	2022			2023 **
Net cash flows provided by (used in) operating activities of discontinued operations		(11,970	)		(3,644	)
Net cash flows provided by (used in) investing activities of discontinued operations		(744	)		76
Net cash flows provided by (used in) financing activities of discontinued operations		10,207			1,781
(Decrease) increase in cash and cash equivalents		(2,506	)		(1,787	)

** Figures for the six-month period ended June 30, 2023 include Calyxt’s results over a five-month period from January 1, 2023 to May 31, 2023

Discontinued Operations - Schedule Of Income Statement Of Discontinued Operations (Detail) - USD ($)
$ / shares in Units, $ in Thousands

3 Months Ended

6 Months Ended

Jun. 30, 2023

Jun. 30, 2022

^[2]

Jun. 30, 2023

Jun. 30, 2022

Schedule Of Income Statement Of Discontinued Operations [Line Items]

Revenues and other income

$ 2,001

$ 2,723

^[1]

$ 5,560

$ 6,523

^[3],[4]

Operating expenses

(25,660)

(30,036)

(52,612)

(63,064)

^[4]

(23,659)

(27,313)

(47,053)

(56,541)

^[4]

15,982

8,301

11,580

9,213

^[4]

$ (5,647)

$ (442)

(10,377)

(6,883)

^[4]

Schedule Of Income Statement Of Discontinued Operations [Line Items]

Revenues and other income

^[5]

Operating expenses

(7,113)

^[5]

(12,856)

(7,070)

^[5]

(12,783)

(3,307)

^[5]

5,900

Basic net income (loss) attributable to shareholders of Cellectis per share ($ /share) from discontinued operations

$ (10,377)

^[5]

$ (6,883)

$ (0.09)

^[6]

$ (0.08)

Diluted net income (loss) attributable to shareholders of Cellectis per share ($ /share) from discontinued operations

$ (0.09)

^[6]

$ (0.08)

[1]	These amounts reflect adjustments made in connection with the presentation of the discontinued operation (Note 5)
[2]	These amounts reflect adjustments made in connection with the presentation of the discontinued operation (Note 5)
[3]	These amounts reflect adjustments made in connection with the presentation of the discontinued operation (Note 5)
[4]	These amounts reflect adjustments made in connection with the presentation of the discontinued operation (Note 5)
[5]	Figures for the six-month period ended June 30, 2023 include Calyxt’s results over a five-month period from January 1, 2023 to May 31, 2023
[6]	Figures for the six-month period ended June 30, 2023 include Calyxt’s results over a five-month period from January 1, 2023 to May 31, 2023

Information Concerning the Group's Consolidated Operations - Revenues by Country of Origin and Other Income (Detail) - USD ($)
$ in Thousands

3 Months Ended

6 Months Ended

Jun. 30, 2023

Jun. 30, 2022

^[1]

Jun. 30, 2023

Jun. 30, 2022

^[3]

Revenue and other operating income

Revenue

$ 178

$ 1,307

^[2]

$ 317

$ 2,972

^[4]

Research tax credit

1,275

1,416

4,391

3,544

Subsidies and other

547

851

Other income

1,823

1,416

^[2]

5,242

3,551

^[4]

2,001

2,723

^[2]

5,560

6,523

^[4]

France [member]

Revenue

178

1,307

317

2,972

United States [member]

Revenue

$ 0

[1]	These amounts reflect adjustments made in connection with the presentation of the discontinued operation (Note 5)
[2]	These amounts reflect adjustments made in connection with the presentation of the discontinued operation (Note 5)
[3]	These amounts reflect adjustments made in connection with the presentation of the discontinued operation (Note 5)
[4]	These amounts reflect adjustments made in connection with the presentation of the discontinued operation (Note 5)

+ References

+ Details

Other current liabilities

6 Months Ended

Jun. 30, 2023

Other current liabilities

Note 13. Other current liabilities


	As of December 31,		As of June 30,
	2022		2023
	$ in thousands
VAT Payables		3,058		-
Accruals for personnel related expenses		9,421		7,126
Other		700		967
Total		13,179		8,093

Accruals for personnel related expenses are related to annual bonuses, paid time-off (PTO) accruals and social expenses on stock options.

Other current liabilities decreased by $5.1 million between December 31, 2022 and June 30 2023 related to the payment of 2022 annual bonuses and the decrease of VAT payables due to the collected VAT on a Servier milestone invoice accrued in December 2022 and paid in 2023.

Right-of-use Assets - Details Information About Breakdown Of Right Of Use Assets (Detail) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance	$ 44,275	$ 69,423
Additions	975	816
Disposals of right-of-use assets	(102)
Depreciation expense	(3,977)	(2,642)
Translation adjustments	286	(369)
Ending balance	41,457	67,227
Gross value at end of period	68,616	89,721
Accumulated depreciation at end of period	(27,159)	(22,494)
Building lease [member]
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance	33,666	55,197
Additions	879	487
Disposals of right-of-use assets	(102)
Depreciation expense	(2,292)	(1,418)
Translation adjustments	237	(304)
Ending balance	32,389	53,962
Gross value at end of period	50,684	69,847
Accumulated depreciation at end of period	(18,295)	(15,885)
Office and laboratory equipment [member]
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance	10,608	14,226
Additions	96	328
Disposals of right-of-use assets	0
Depreciation expense	(1,685)	(1,225)
Translation adjustments	49	(64)
Ending balance	9,068	13,265
Gross value at end of period	17,932	19,875
Accumulated depreciation at end of period	$ (8,864)	$ (6,609)

Trade receivables and other current assets

6 Months Ended

Jun. 30, 2023

Trade receivables and other current assets

Note 10. Trade receivables and other current assets

10.1 Trade receivables


	As of December 31,		As of June 30,
	2022		2023
	$ in thousands
Trade receivables		772		422
Total net value of trade receivables		772		422

All trade receivables have payment terms of less than one year. The trade receivables as of June 30, 2023 primarily consists of $0.2 million receivable related to our license agreement with one of our partner. The diminution between December 31, 2022 and June 30, 2023 is related to the payment of a $0.5 million receivable related to the extension of the option term of a license agreement.

10.2 Subsidies receivables


	As of December 31,		As of June 30,
	2022		2023
	$ in thousands
Research tax credit		14,496		19,180
Other subsidies		—		308
Total subsidies receivables		14,496		19,488

Research tax credit receivables as of June 30, 2023 include the accrual for the French research tax credit related to 2023 for $3.4 million and to previous periods for $15.8 million.

The remaining amount relates to refundable tax credits in the United States.

During December 2018, the French Tax Authority initiated an audit related to the 2014, 2015, 2016 and 2017 French research tax credits. In January 2022, the tribunal administratif of Paris, France confirmed that Cellectis was entitled to receive the amounts related to 2017 and 2018 tax credits. $0.8 million were reimbursed to Cellectis in February 2022. On March 15, 2022, the French tax authorities appealed this decision to the Paris Administrative Court of Appeal (Cour administrative d’appel de Paris) and requested that the decision be reversed. On May 18, 2022, the Company filed its observations in defense, so that the litigation is pending the Court’s decision.

On March 8, 2023, we signed a grant and refundable advance agreement with BPI to partially support one of our R&D programs which correspond to UCART 20x22 and related CMC activities. Pursuant to this agreement, we will receive, subject to the achievement of certain milestones, a total financing of €6.4 million of which 14.77% is a grant and 85.23% is a refundable advance.

The first instalment of €1.0 million, which represents an upfront amount, became payable upon signature and was partially received in the second quarter of 2023. The first milestone payment of €1.9 million, which corresponds to the start of the UCART 20x22 clinical study, has also become payable and is expected to be received in the third quarter of 2023. The part of those initial payments corresponding to a grant was recognized in other revenues for $0.3 million.

10.3 Other current assets


	As of December 31,		As of June 30,
	2022		2023
	$ in thousands
VAT receivables		1,140		999
Prepaid expenses and other prepayments		6,233		5,979
Tax and social receivables		1,166		63
Deferred expenses and other current assets		538		828
Total other current assets		9,078		7,869

Prepaid expenses and other prepayments primarily include advances to our sub-contractors on research and development activities. These mainly relate to advance payments to suppliers of biological raw materials and to third parties participating in product manufacturing.

During the year ended December 31, 2022, and the six-month period ended June 30, 2023, we prepaid certain manufacturing costs related to our product candidates UCART 123, UCART 22 and UCART 20x22.

As of December 31, 2022 and June 30, 2023, tax and social receivables relate mainly to social charges on personnel expenses. The reduction is related to reimbursement of tax litigation on stock options.

The increase in deferred expenses and other current assets of $0.3 million from December 31, 2022 to June 30, 2023 is mainly due to a $0.4 million receivable related to our American Depositary Receipts program.

Non-cash stock-based compensation (Tables)

6 Months Ended

Jun. 30, 2023

Summary of Number of Shares Outstanding and Weighted Average Grant Date Fair Value

Information on free shares activity follows:


	Number of Free shares Outstanding			Weighted-Average Grant Date Fair Value
Unvested balance of December 31, 2021		922,701			14.15	€
Granted		354,770			2.79	€
Vested		(191,658	)		17.96	€
Cancelled		(176,700	)		13.99	€
Unvested balance as of December 31, 2022		909,113			11.18	€
Granted		342,900			3.08	€
Vested
Cancelled		(36,112	)		11.10	€
Unvested balance as of June 30, 2023		1,215,901			8.90	€

Stock options [member]

Summary of Information on Stock Option Activity

Information on stock option activity follows:


	Options Exercisable		Weighted-Average Exercise Price Per Share			Options Outstanding			Weighted-Average Exercise Price Per Share			Remaining Average Useful Life
Balance as of December 31, 2021		7,566,679		24.78	€		9,159,794			23.50	€		5.3	y
Granted				-			828,549			4.18	€
Exercised				-
Forfeited or Expired				-			(1,201,079	)		18.85	€

Balance as of December 31, 2022		7,400,519		24.58	€		8,787,264			22.31	€		4.6	y
Granted				-			1,835,411			2.86	€
Exercised				-			-			-
Forfeited or Expired				-			(22,638	)		18.29	€

Balance as of June 30, 2023		7,800,007		23.84	€		10,600,037			18.95	€		5.1	y

Summary of assumptions Vesting Details

The weighted-average fair values of stock options granted and the assumptions used for the Black-Scholes option pricing model were as follows:


	2022	2023
Weighted-Average fair values of stock options granted	1.31€	1.65€
Assumptions:
Risk-free interest rate	0.00% - 2.49%	2.45% - 2.75%
Share entitlement per options	1	1
Exercise price	2.09€ - 7.22€	1.74€ - 3.17€
Grant date share fair value	1.91€-6.74€	1.70€-3.09€
Expected volatility	58.7% - 62.5%	63.7% - 64.4%
Expected term (in years)	6.03 - 6.15	6.03 - 6.15
Vesting conditions	Performance or Service	Performance or Service
Vesting period	Graded	Graded

Non Employee Warrants [Member]

Summary of Information on Stock Option Activity

Information on non-employee warrants activity follows:


	Warrants Exercisable		Weighted-Average Exercise Price Per Share			Warrants Outstanding		Weighted-Average Exercise Price Per Share			Remaining Average Useful Life
Balance as of December 31, 2021		896,225		27.18	€		896,225		27.18	€		4.3	y
Granted
Exercised
Forfeited or Expired

Balance as of December 31, 2022		896,225		27.18	€		896,225		27.18	€		3.3	y
Granted
Exercised
Forfeited or Expired

Balance as of June 30, 2023		896,225		27.18	€		896,225		27.18	€		2.8	y

Earnings Per Share - Details of Earnings Per Share (Detail) - USD ($)
$ / shares in Units, $ in Thousands

3 Months Ended

6 Months Ended

Jun. 30, 2023

Jun. 30, 2022

^[1]

Jun. 30, 2023

Jun. 30, 2022

Earnings per share [abstract]

Net income (loss) attributable to shareholders of Cellectis ($ in thousands)

$ (40,715)

$ (50,858)

Net income (loss) attributable to shareholders of Cellectis ($ in thousands) from discontinued operations

$ (4,984)

$ (3,531)

Adjusted weighted average number of outstanding shares, used to calculate both basic and diluted net result per share

53,541,010

45,497,127

Basic net income (loss) attributable to shareholders of Cellectis per share ( $ /share)

$ (0.19)

$ (0.42)

$ (0.76)

$ (1.12)

^[2]

Basic earnings (loss) per share from discontinued operations

(0.05)

(0.09)

(0.08)

^[2]

Diluted net income (loss) attributable to shareholders of Cellectis per share ( $ /share)

(0.19)

(0.42)

(0.76)

(1.12)

^[2]

Diluted earnings from discontinued operations per share ( $ /share)

$ (0.05)

$ 0

$ (0.09)

$ (0.08)

^[2]

[1]	These amounts reflect adjustments made in connection with the presentation of the discontinued operation (Note 5)
[2]	These amounts reflect adjustments made in connection with the presentation of the discontinued operation (Note 5)

Financial liabilities (Tables)

6 Months Ended

Jun. 30, 2023

Detail of financial liabilities


	As of December 31,		As of June 30,
	2022		2023
	$ in thousands
Conditional advances		—		417
Lease debts		49,358		46,157
State Guaranteed loan « PGE »		13,569		11,314
EIB loan		—		16,654
EIB warrants		—		4,875
Other non-current financial liabilities		6,962		7,010
Total non-current financial liabilities and non-current lease debts		69,889		86,427
Lease debts		7,872		8,270
State Guaranteed loan « PGE »		4,972		5,064
Other current financial liabilities		116		122
Total current financial liabilities and current lease debts		12,960		13,455
Trade payables		21,456		19,229
Other current liabilities		13,179		8,093
Total Financial liabilities		117,484		127,204

Schedule of Assumptions and Results of Warrants Valuation

The assumptions and results of the warrants valuation are detailed in the following tables:


		Warrants Tranche A
Grant date *		4/17/2023
Expiration date		4/17/2043
Number of options granted		2,779,188
Share entitlement per option		1
Exercise price (in euros per option)		1.92
Valuation method		Longstaff Schwartz

* The grant date retained is the disbursement date of the Tranche A as this is the issuance date defined in the contract.


	Warrants Tranche A
	4/17/2023			6/30/2023
Number of warrants granted	2,779,188			2,779,188
Share price (in euros)	1.87			1.77
Average life of options (in years)	20			19.8
Expected volatility	81.3%				70.6	%
Put option cap (in € thousands)	7.196			7.196
Discount rate	2.85%			2.71%
Expected dividends		0	%		0	%
Fair value per options (in euros per share)	1.73			1.61
Fair value in $ thousands		5,224			4,875

Schedule of Sensitivity Of The Fair Value To The Expected Volatility

We conducted sensitivity analysis on the expected volatility. As shown in the tables below, the sensitivity of the fair value to the expected volatility is not significant:


As of April 17, 2023	Fair value in $ thousands
Expected volatility -5%		5,206
Expected volatility		5,224
Expected volatility +5%		5,231


As of June 30, 2023	Fair value in $ thousands
Expected volatility -5%		4,790
Expected volatility		4,875
Expected volatility +5%		4,925

Due dates of the financial liabilities


Balance as of June 30, 2023	Book value		Less than One Year		One to Five Years		More than Five Years
	$ in thousands
Lease debts		54,427		8,270		28,661		17,496
Financial liabilities		45,455		5,185		17,886		22,384
Financial liabilities		99,882		13,455		46,547		39,879
Trade payables		19,229		19,229		—		—
Other current liabilities		8,093		8,093		—		—
Total financial liabilities		127,204		40,777		46,547		39,879

Non-cash stock-based compensation

6 Months Ended

Jun. 30, 2023

Non-cash stock-based compensation

Note 16. Non-cash stock-based compensation

16.1 Detail of Cellectis equity awards

Holders of vested Cellectis stock options and non-employee warrants are entitled to exercise such options and warrants to purchase Cellectis ordinary shares at a fixed exercise price established at the time such options and warrants are granted during their useful life.

For stock options and non-employee warrants, we estimate the fair value of each option on the grant date or other measurement date if applicable using a Black-Scholes option-pricing model, which requires us to make predictive assumptions regarding future stock price volatility, employee exercise behavior, dividend yield, and the forfeiture rate. We estimate our future stock price volatility based on Cellectis historical closing share prices over the expected term period. Our expected term represents the period of time that options granted are expected to be outstanding determined using the simplified method. The risk-free interest rate for periods during the expected term of the options is based on the French government securities with maturities similar to the expected term of the options in effect at the time of grant. We have never declared or paid any cash dividends and do not presently plan to pay cash dividends in the foreseeable future. Consequently, we used an expected dividend yield of zero. Options may be priced at 100 percent or more of the fair market value on the date of grant, and generally vest over four years after the date of grant. Options generally expire within ten years after the date of grant.

Stock Options

The weighted-average fair values of stock options granted and the assumptions used for the Black-Scholes option pricing model were as follows:


	2022	2023
Weighted-Average fair values of stock options granted	1.31€	1.65€
Assumptions:
Risk-free interest rate	0.00% - 2.49%	2.45% - 2.75%
Share entitlement per options	1	1
Exercise price	2.09€ - 7.22€	1.74€ - 3.17€
Grant date share fair value	1.91€-6.74€	1.70€-3.09€
Expected volatility	58.7% - 62.5%	63.7% - 64.4%
Expected term (in years)	6.03 - 6.15	6.03 - 6.15
Vesting conditions	Performance or Service	Performance or Service
Vesting period	Graded	Graded

Information on stock option activity follows:


	Options Exercisable		Weighted-Average Exercise Price Per Share			Options Outstanding			Weighted-Average Exercise Price Per Share			Remaining Average Useful Life
Balance as of December 31, 2021		7,566,679		24.78	€		9,159,794			23.50	€		5.3	y
Granted				-			828,549			4.18	€
Exercised				-
Forfeited or Expired				-			(1,201,079	)		18.85	€

Balance as of December 31, 2022		7,400,519		24.58	€		8,787,264			22.31	€		4.6	y
Granted				-			1,835,411			2.86	€
Exercised				-			-			-
Forfeited or Expired				-			(22,638	)		18.29	€

Balance as of June 30, 2023		7,800,007		23.84	€		10,600,037			18.95	€		5.1	y

Share-based compensation expense related to stock option awards was $1.4 million and $1.8 million for the six-month period ended June 30, 2023, and 2022, respectively.

On January 24, 2023, the Board of Directors granted 1,417,321 stock options. For executive employees, stock options vesting period is over four years and based on performance criteria. For all other beneficiaries, the vesting period for stock options is over four years and without performance criteria.

On May 4, 2023, the Board of Directors granted 358,100 stock options. For executive employees, stock options vesting period is over four years and based on performance criteria. For all other beneficiaries, the vesting period for stock options is over four years and without performance criteria.

On June 26, 2023, the Board of Directors granted 55,690 stock options to non executive employees. The vesting period for stock options is over four years and without performance criteria.

Non-Employee Warrants

No non-employee warrants (or “Bons de Souscriptions d’Actions” or “BSAs”) have been granted during the periods presented.

Information on non-employee warrants activity follows:


	Warrants Exercisable		Weighted-Average Exercise Price Per Share			Warrants Outstanding		Weighted-Average Exercise Price Per Share			Remaining Average Useful Life
Balance as of December 31, 2021		896,225		27.18	€		896,225		27.18	€		4.3	y
Granted
Exercised
Forfeited or Expired

Balance as of December 31, 2022		896,225		27.18	€		896,225		27.18	€		3.3	y
Granted
Exercised
Forfeited or Expired

Balance as of June 30, 2023		896,225		27.18	€		896,225		27.18	€		2.8	y

Considering that all non-employee warrants have vested, there was no share-based compensation expense related to non-employee warrants awards for the six-month period ended June 30, 2023 and June 30, 2022.

Free shares

The free shares granted prior to 2018 are subject to a two-year vesting period and additional two-year holding period for French residents and four-years vesting period for foreign residents.

The free shares granted in 2018 and until 2021 are subject to at least one-year vesting and additional one-year vesting period for French residents and two-years vesting period for foreign residents. The vesting of free shares granted to executive officers of the Company in October 2020 are subject to performance conditions with a minimum vesting of a 3-year period.

The free shares granted in 2021 and after are subject to a three-year vesting period for all employees, provided that the free shares granted to executive officers are subject to performance conditions with a minimum vesting of a 3-year period.

Information on free shares activity follows:


	Number of Free shares Outstanding			Weighted-Average Grant Date Fair Value
Unvested balance of December 31, 2021		922,701			14.15	€
Granted		354,770			2.79	€
Vested		(191,658	)		17.96	€
Cancelled		(176,700	)		13.99	€
Unvested balance as of December 31, 2022		909,113			11.18	€
Granted		342,900			3.08	€
Vested
Cancelled		(36,112	)		11.10	€
Unvested balance as of June 30, 2023		1,215,901			8.90	€

The fair value of free shares corresponds to the grant date share fair value.

We have never declared or paid any cash dividends and do not presently plan to pay cash dividends in the foreseeable future. Consequently, we used an expected dividend yield of zero in determining fair value.

Share-based compensation expense related to free shares awards was $1.9 million and $2.5 million for the six-month period ended June 30, 2023 and 2022, respectively.

On January 24, 2023, the Board of Directors granted 340,750 free shares. The vesting period is three years and without performance criteria.

16.2 Detail of Calyxt equity awards

Pursuant to Calyxt’s deconsolidation, stock and share-based compensation expenses until May 31, 2023 were classified as discontinued operations.

Stock-based compensation expense related to stock option awards was $0.8 million, compared to an expense of $0.9 million due to options forfeiture or expiration for the six-month period ended June 30, 2023 and 2022, respectively.

Share-based compensation expense related to restricted stock units awards was $0.5 million, compared to an expense of $0.7 million due to options forfeiture or expiration for the six-month periods ended June 30, 2023 and 2022, respectively.

Share-based compensation expense related to performance stock units awards was $0.3 million, compared to an expense of $0.3 million for the six-month periods ended June 30, 2023 and 2022, respectively.

Trade Receivables and Other Current Assets - Disclosure of Subsidies Receivables (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Receivables1 [abstract]
Research tax credit	$ 19,180	$ 14,496
Other subsidies	308	0
Total subsidies receivables	$ 19,488	$ 14,496

Financial Liabilities - Schedule Representing Due Dates of the Financial Liabilities (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Disclosure of offsetting of financial liabilities [line items]
Lease liabilities	$ 54,427
Financial liabilities	45,455
Financial liabilities	99,882
Trade payables	19,229	$ 21,456
Other current liabilities	8,093	13,179
Total financial liabilities	127,204	$ 117,484
Less than One Year [member]
Disclosure of offsetting of financial liabilities [line items]
Lease liabilities	8,270
Financial liabilities	5,185
Financial liabilities	13,455
Trade payables	19,229
Other current liabilities	8,093
Total financial liabilities	40,777
One to Five Years [member]
Disclosure of offsetting of financial liabilities [line items]
Lease liabilities	28,661
Financial liabilities	17,886
Financial liabilities	46,547
Trade payables	0
Other current liabilities	0
Total financial liabilities	46,547
More than Five Years [member]
Disclosure of offsetting of financial liabilities [line items]
Lease liabilities	17,496
Financial liabilities	22,384
Financial liabilities	39,879
Trade payables	0
Other current liabilities	0
Total financial liabilities	$ 39,879

Information Concerning the Group's Consolidated Operations - Details of Financial Income and Expenses (Detail) - USD ($)
$ in Thousands

3 Months Ended

6 Months Ended

12 Months Ended

Jun. 30, 2023

Jun. 30, 2022

Jun. 30, 2023

Jun. 30, 2022

Dec. 31, 2022

Finance income expense [abstract]

Income from cash, cash equivalents and financial assets

$ 761

$ 205

$ 1,441

$ 311

Foreign exchange gain

9,216

6,146

9,248

8,310

$ 8,300

Gain on fair vaue measurment

531

3,642

593

3,642

Other financial income

21,759

Total financial revenues

32,266

9,992

^[1]

33,041

12,263

^[2]

Interest on financial liabilities

(573)

(111)

(690)

(176)

Foreign exchange loss

(1,289)

(592)

(2,278)

(878)

$ (900)

Loss on fair value measurement

(13,648)

(125)

(16,931)

(247)

Interest on lease liabilities

(774)

(863)

(1,561)

(1,748)

Other financial expenses

(1)

Total financial expenses

(16,284)

(1,691)

^[1]

(21,461)

(3,050)

^[2]

Net Financial gain (loss)

$ 15,982

$ 8,301

^[1]

$ 11,580

$ 9,213

^[2]

[1]	These amounts reflect adjustments made in connection with the presentation of the discontinued operation (Note 5)
[2]	These amounts reflect adjustments made in connection with the presentation of the discontinued operation (Note 5)

Financial liabilities - Additional Information (Detail)
€ / shares in Units, € in Millions

3 Months Ended

6 Months Ended

Apr. 17, 2023

EUR (€)

Apr. 17, 2023

USD ($)

Mar. 28, 2023

TradingDay

€ / shares

Mar. 08, 2023

USD ($)

Dec. 28, 2022

EUR (€)

Jun. 30, 2023

USD ($)

Jun. 30, 2022

USD ($)

^[1]

Jun. 30, 2023

USD ($)

Jun. 30, 2022

USD ($)

^[2]

Jun. 30, 2023

EUR (€)

Jun. 30, 2023

USD ($)

Jun. 19, 2023

USD ($)

Apr. 04, 2023

EUR (€)

Dec. 31, 2022

USD ($)

Jun. 30, 2022

EUR (€)

Jun. 30, 2022

USD ($)

Disclosure of offsetting of financial liabilities [line items]

Secured Borrowings

$ 20,100,000

State Guaranteed Loan, value

20,100,000

Research and development expense

$ 22,144,000

$ 25,630,000

$ 43,225,000

$ 52,231,000

Non-current financial liabilities

40,270,000

$ 20,531,000

Tranche A Warrants [Member]

Disclosure of offsetting of financial liabilities [line items]

Fair value of loan

$ 5,224,000

4,875,000

Research Tax Credit Financing [Member]

Disclosure of offsetting of financial liabilities [line items]

Cash received | €

€ 5.5

Non-current financial liabilities

$ 5,900,000

Cash | €

€ 5.5

New York [Member]

Disclosure of offsetting of financial liabilities [line items]

Non-current financial liabilities

1,100,000

$ 1,100,000

State Guaranteed Loan [Member]

Disclosure of offsetting of financial liabilities [line items]

Secured Borrowings | €

€ 18.5

State Guaranteed Loan, value | €

€ 18.5

Guaranteed borrowing amount, percentage

90.00%

Current liability of loan

5,100,000

Non current liability of loan

$ 11,300,000

State Guaranteed Loan [Member] | Bottom of range [member]

Disclosure of offsetting of financial liabilities [line items]

State Guaranteed Loan [Member] | Top of range [member]

0.31%

Disclosure of offsetting of financial liabilities [line items]

Disclosure of offsetting of financial liabilities [line items]

3.35%

Conditional Advances

Discounting adjustment expected

$ 200

Market rate based on credit spread observed loans

3.04%

16.10%

Amount to be repaid

$ 1,000

Cash received

$ 900,000

Fair value grant amount

500,000

Fair value of loan

$ 400,000

Cash

$ 900,000

European Investment Bank Loan [Member]

Disclosure of offsetting of financial liabilities [line items]

Minimum voluntary payment percentage

€ 40.0

75.00%

European Investment Bank Loan [Member] | Funding Contract Tranche A [Member]

Disclosure of offsetting of financial liabilities [line items]

Borrowings | €

€ 20.0

Effective interest rate

13.40%

Initial fair value of loan

€ 20.0

$ 16,200,000

Transaction costs

300,000

Fair value of warrants

$ 5,200,000

European Investment Bank Loan [Member] | Funding Contract Tranche A [Member] | Financial liabilities at amortised cost, class [member]

Disclosure of offsetting of financial liabilities [line items]

European Investment Bank Loan [Member] | Funding Contract Tranche B [Member]

20.0

Disclosure of offsetting of financial liabilities [line items]

European Investment Bank Loan [Member] | Funding Contract Tranche C [Member]

15.0

Disclosure of offsetting of financial liabilities [line items]

European Investment Bank Loan [Member] | Tranche A Warrants [Member]

€ 5.0

Disclosure of offsetting of financial liabilities [line items]

Outstanding share capital percentage

8.00%

Warrants Issued | shares

2,779,188

5.00%

Exercise price per share or per unit of warrants or rights outstanding | € / shares

€ 1.92

Percentage of volume weighted average price per share

99.00%

Number of trading days | TradingDay

Warrants maturity period

6 years

Proceeds from issue of warrants | €

€ 20.0

Class of warrants or right number of securities called by each warrants or right | shares

Percentage of weighted average price per share

99.00%

European Investment Bank Loan [Member] | Bottom of range [member]

Disclosure of offsetting of financial liabilities [line items]

Ratio of warrants amount disbursed

0.3

[1]	These amounts reflect adjustments made in connection with the presentation of the discontinued operation (Note 5)
[2]	These amounts reflect adjustments made in connection with the presentation of the discontinued operation (Note 5)

Earnings per share

6 Months Ended

Jun. 30, 2023

Earnings per share

Note 17. Earnings per share


	For the six-month period ended June 30,
	2022			2023
Net income (loss) attributable to shareholders of Cellectis ($ in thousands)		(50,858	)		(40,715	)
Net income (loss) attributable to shareholders of Cellectis ($ in thousands) from discontinued operations		(3,531	)		(4,984	)
Adjusted weighted average number of outstanding shares, used to calculate both basic and diluted net result per share		45,497,127			53,541,010
Basic / Diluted net income (loss) per share attributable to shareholders of Cellectis
Basic net income (loss) attributable to shareholders of Cellectis per share ($ /share)		(1.12	)		(0.76	)
Basic earnings from discontinued operations per share ($ /share)		(0.08	)		(0.09	)
Diluted net income (loss) attributable to shareholders of Cellectis per share ($ /share)		(1.12	)		(0.76	)
Diluted earnings from discontinued operations per share ( $ /share)		(0.08	)		(0.09	)

When we have adjusted net loss, we use the weighted average number of outstanding shares, basic to compute the diluted adjusted net income (loss) attributable to shareholders of Cellectis ($/share). When we have adjusted net income, we use the weighted average number of outstanding shares, diluted to compute the diluted adjusted net income (loss) attributable to shareholders of Cellectis ($/share).

Property, Plant and Equipment - Disclosure of Property, Plant and Equipment (Detail) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	$ 63,621	$ 78,846
Additions to tangible assets	556	945
Disposal of tangible assets	(326)	(90)
Reclassification	1	23
Depreciation expense	(4,872)	(2,827)
Translation adjustments	252	(327)
Ending balance	59,231	76,523
Gross value at end of period	97,318	105,955
Accumulated depreciation and impairment at end of period	(38,087)	(29,432)
Land and Buildings [member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	9,321	14,733
Additions to tangible assets	0	78
Disposal of tangible assets	(172)	0
Reclassification	(290)	(78)
Depreciation expense	(948)	(571)
Translation adjustments	171	(212)
Ending balance	8,661	14,106
Gross value at end of period	18,193	22,227
Accumulated depreciation and impairment at end of period	(9,532)	(8,121)
Technical Equipment [member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	51,072	58,072
Additions to tangible assets	15	23
Disposal of tangible assets	(152)	54
Reclassification	(81)	(1,254)
Depreciation expense	(3,570)	(2,139)
Translation adjustments	51	(71)
Ending balance	47,497	57,146
Gross value at end of period	73,035	76,379
Accumulated depreciation and impairment at end of period	(25,537)	(19,233)
Fixtures, Fittings and Other Equipment [member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	2,277	3,109
Additions to tangible assets	11	96
Disposal of tangible assets	(1)	(143)
Reclassification	0	(8)
Depreciation expense	(354)	(117)
Translation adjustments	12	(19)
Ending balance	1,946	2,933
Gross value at end of period	4,963	5,012
Accumulated depreciation and impairment at end of period	(3,018)	(2,078)
Assets Under Construction [member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	952	2,932
Additions to tangible assets	529	793
Disposal of tangible assets	0	0
Reclassification	372	1,362
Depreciation expense	0	0
Translation adjustments	18	(25)
Ending balance	1,127	2,338
Gross value at end of period	1,127	2,338
Accumulated depreciation and impairment at end of period	$ 0	$ 0

Right-of-use Assets - Additional Information (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	May 31, 2023	Dec. 31, 2022	Jun. 30, 2022	Dec. 31, 2021
Disclosure of quantitative information about right-of-use assets [line items]
Right-of-use assets	$ 41,457		$ 44,275	$ 67,227	$ 69,423
Calyxt [Member]
Disclosure of quantitative information about right-of-use assets [line items]
Right-of-use assets	$ 0	$ 13,139	$ 13,263

Information Concerning the Group's Consolidated Operations - Summary of Key Performance Indicators by Reportable Segments (Detail) - USD ($)
$ in Thousands

3 Months Ended

6 Months Ended

Jun. 30, 2023

Jun. 30, 2022

Jun. 30, 2023

Jun. 30, 2022

$ 178

$ 1,307

^[1],[2]

$ 317

$ 2,972

^[3],[4]

1,823

1,416

^[1],[2]

5,242

3,551

^[3],[4]

2,001

2,723

^[1],[2]

5,560

6,523

^[3],[4]

(55)

(329)

^[2],[5]

(389)

(714)

^[4],[6]

(22,144)

(25,630)

^[2]

(43,225)

(52,231)

^[4]

(3,950)

(4,830)

^[2]

(8,914)

(10,893)

^[4]

490

753

^[2],[5]

(83)

774

^[4],[6]

(25,660)

(30,036)

^[2]

(52,612)

(63,064)

^[4]

(23,659)

(27,313)

^[2]

(47,053)

(56,541)

^[4]

15,982

8,301

^[2]

11,580

9,213

^[4]

258

^[2]

(258)

^[4]

(5,647)

(442)

^[2]

(10,377)

(6,883)

^[4]

Profit (loss), attributable to non-controlling interests

(13,583)

(19,454)

^[2]

(46,108)

(54,211)

^[4],[7]

(2,935)

(506)

^[2]

(5,393)

(3,352)

^[4]

Net income (loss) attributable to shareholders of Cellectis

(10,648)

(18,946)

^[2]

(40,715)

(50,858)

^[4]

IFRS 5 [Member]

2,002

2,765

5,602

6,596

(118)

(329)

(451)

(714)

(23,467)

(29,048)

(46,712)

(58,527)

(4,927)

(8,415)

(11,227)

(17,695)

(584)

951

(1,334)

1,016

(29,095)

(36,842)

(59,725)

(75,920)

(27,093)

(34,077)

(54,123)

(69,324)

13,769

14,623

8,273

15,113

(258)

(5,647)

(442)

(10,377)

(6,883)

Profit (loss), attributable to non-controlling interests

(13,583)

(19,454)

(46,108)

(54,211)

(2,935)

506

5,393

3,352

Net income (loss) attributable to shareholders of Cellectis

(10,648)

(18,946)

(40,715)

(50,858)

Adjustment of share-based compensation attributable to shareholders of Cellectis

2,074

2,684

4,053

5,331

Adjusted net income (loss) attributable to shareholders of Cellectis

(8,573)

(16,264)

(36,662)

(45,527)

Depreciation and amortization

(4,431)

(5,108)

(8,882)

(10,749)

Additions to tangible and intangible assets

332

1,178

556

2,123

Research and Development [member] | IFRS 5 [Member]

Adjustment of share-based compensation attributable to shareholders of Cellectis

900

1,681

2,088

3,349

Selling, General and Administration [member] | IFRS 5 [Member]

Adjustment of share-based compensation attributable to shareholders of Cellectis

1,174

1,003

1,965

1,982

Plants [member] | IFRS 5 [Member]

(63)

(1,322)

(3,419)

(3,487)

(6,297)

(976)

(3,585)

(2,313)

(6,801)

(1,074)

198

(1,251)

242

(3,435)

(6,806)

(7,113)

(12,856)

(3,434)

(6,764)

(7,070)

(12,783)

(2,213)

6,322

(3,307)

5,900

(5,647)

(442)

(10,377)

(6,883)

Profit (loss), attributable to non-controlling interests

(5,647)

(442)

(10,377)

(6,883)

(2,935)

506

5,393

3,352

Net income (loss) attributable to shareholders of Cellectis

(2,712)

(4,984)

(3,531)

Adjustment of share-based compensation attributable to shareholders of Cellectis

428

673

788

1,005

Adjusted net income (loss) attributable to shareholders of Cellectis

(2,284)

737

(4,196)

(2,526)

Depreciation and amortization

(12)

(608)

(7)

(1,316)

Additions to tangible and intangible assets

308

671

Plants [member] | Research and Development [member] | IFRS 5 [Member]

Adjustment of share-based compensation attributable to shareholders of Cellectis

103

226

188

216

Plants [member] | Selling, General and Administration [member] | IFRS 5 [Member]

Adjustment of share-based compensation attributable to shareholders of Cellectis

326

447

599

789

Therapeutics [member] | IFRS 5 [Member]

2,001

2,723

5,560

6,523

(55)

(329)

(389)

(714)

(22,144)

(25,630)

(43,225)

(52,231)

(3,950)

(4,830)

(8,914)

(10,893)

490

753

(83)

774

(25,660)

(30,036)

(52,612)

(63,064)

(23,659)

(27,313)

(47,053)

(56,541)

15,982

8,301

11,580

9,213

(258)

Profit (loss), attributable to non-controlling interests

(7,935)

(19,012)

(35,731)

(47,328)

Net income (loss) attributable to shareholders of Cellectis

(7,935)

(19,012)

(35,731)

(47,328)

Adjustment of share-based compensation attributable to shareholders of Cellectis

1,646

2,011

3,265

4,327

Adjusted net income (loss) attributable to shareholders of Cellectis

(6,289)

(17,001)

(32,465)

(43,001)

Depreciation and amortization

(4,419)

(4,500)

(8,875)

(9,434)

Additions to tangible and intangible assets

311

870

536

1,452

Therapeutics [member] | Research and Development [member] | IFRS 5 [Member]

Adjustment of share-based compensation attributable to shareholders of Cellectis

797

1,454

1,900

3,134

Therapeutics [member] | Selling, General and Administration [member] | IFRS 5 [Member]

Adjustment of share-based compensation attributable to shareholders of Cellectis

849

557

1,366

1,193

Operating Segments [member] | IFRS 5 [Member]

179

1,348

360

3,045

Operating Segments [member] | Plants [member] | IFRS 5 [Member]

1,823

1,416

5,242

3,551

Operating Segments [member] | Therapeutics [member] | IFRS 5 [Member]

178

1,307

317

2,972

$ 1,823

$ 1,416

$ 5,242

$ 3,551

[1]	These amounts reflect adjustments made in connection with the presentation of the discontinued operation (Note 5)
[2]	These amounts reflect adjustments made in connection with the presentation of the discontinued operation (Note 5)
[3]	These amounts reflect adjustments made in connection with the presentation of the discontinued operation (Note 5)
[4]	These amounts reflect adjustments made in connection with the presentation of the discontinued operation (Note 5)
[5]	These amounts reflect adjustments made in connection with the presentation of the discontinued operation (Note 5)
[6]	These amounts reflect adjustments made in connection with the presentation of the discontinued operation (Note 5)
[7]	These amounts reflect adjustments made in connection with the presentation of the discontinued operation (Note 5)

Scope of consolidation and non-consolidated entities

6 Months Ended

Jun. 30, 2023

Scope of consolidation and non-consolidated entities

Note 3. Scope of consolidation and non-consolidated entities

Consolidated entities

As of June 30, 2023, Cellectis S.A. owns 100% of Cellectis, Inc., which owns 100% of Cellectis Biologics, Inc.

For the six-month periods ended June 30, 2023 the consolidated group of companies (sometimes referred to as the “Group”) includes Cellectis S.A., Cellectis, Inc. and Cellectis Biologics, Inc and Calyxt, Inc. through May 31, 2023, the date of deconsolidation. See Non-consolidated entities below.

For the six-month periods ended June 30, 2022 the consolidated group of companies (sometimes referred to as the “Group”) includes Cellectis S.A., Cellectis, Inc., Cellectis Biologics, Inc and Calyxt, Inc.

Investments in associates

On December 29, 2022, we entered into a Collaboration Agreement with Primera Therapeutics, Inc. (“Primera”) (the “Primera Collaboration Agreement”). Under the Primera Collaboration Agreement, Primera and Cellectis will be co-developing a mitochondrial DNA engineering toolbox for therapies to treat mitochondrial diseases.

Cellectis brings its experience in groundbreaking gene editing research, technology, manufacturing and clinical development. In consideration for Cellectis giving access to Primera to its expertise and knowledge in the gene editing field, and for the Cellectis’ development activities pursuant to the development plan agreed upon the parties. The Primera Collaboration Agreement also grants Primera a right to exercise an exclusive worldwide option to obtain a license from Cellectis on up to five product candidates developed under the Primera Collaboration Agreement. Upon Primera exercising the option, Cellectis would be eligible to receive milestone payments and royalty payments on the net sales of the products developed under the Primera Collaboration Agreement.

Pursuant to the Primera Collaboration Agreement, on May 17, 2023, Cellectis and Primera entered into a Subscription Agreement and a Shareholders Agreement under which Cellectis received 234,570 shares of common stock of Primera, representing a 19.0% ownership interest and 19% of the voting rights in Primera at that date, and a right to designate a director to the Primera’s board of directors.

Consequently, we consider that, since May 17, 2023, we have a significant influence over Primera as defined by IAS 28 because, in addition to voting rights, Cellectis receives and actively holds a seat on Primera’s Board and Cellectis provides Primera with access to essential technical information. Therefore, our investment on Primera is accounted for using the equity method starting on May 17, 2023.

On initial recognition, the investment in an associate is recognized at cost. We consider that the best estimate of the fair value of the consideration given to Primera is the fair market value of Primera’s shares received by Cellectis. The fair value of the investment is immaterial.

As of June 30, 2023, after Primera’s share capital increase that occurred during the quarter, we hold 17.0% of Primera’s shares and voting rights and consider that we continue to exercise significant influence over Primera. After taking into account Primera’s net loss between May 17, 2023 and June 30, 2023 and applying our ownership rate, the value of our investment remains immaterial. We have no legal or contractual obligation to bear losses in excess of our share.

In view of the immaterial value of our investment in Primera at inception and June 30, 2023, we do not present the investment in associates on a separate line in our consolidated statements of financial position or our consolidated statements of operations. Our share of Primera’s loss as of June 30, 2023 has been recognized in other operating expenses.

Non-consolidated entities

Calyxt was consolidated until May 31, 2023.

On November 23, 2022, Calyxt received a non-binding letter of intent from Cibus Global regarding a potential reverse merger with Calyxt (with Calyxt absorbing Cibus Global). With Calyxt as the surviving entity, current equityholders of Cibus Global would receive shares of Calyxt common stock issued for the purpose of the transaction. On January 13, 2023, Calyxt, Calypso Merger Subsidiary, LLC, a wholly-owned subsidiary of Calyxt, Cibus Global and certain other parties, entered into the Merger Agreement with respect to this Merger. Upon completion of the proposed Merger, Cellectis S.A. was expected to own approximately 2.4% of the equity interests of the merged combined company, resulting in a loss of control by Cellectis over Calyxt.

In this context, since November 23, 2022, and for long as Cellectis retained control over Calyxt, the assets and liabilities of Calyxt are presented in the financial statements as non-current assets and liabilities held for sale for all periods presented, in accordance with IFRS 5. The statements of consolidated operations, statements of consolidated comprehensive income and statements of consolidated cash flows reflect the presentation of Calyxt as a discontinued operation for all period presented, with a restatement of the 2022 statements.

On May 31, 2023 immediately prior to the consummation of the Merger, Cellectis S.A.’s ownership interest in Calyxt amounted to 48.0%. Cellectis’ voting rights continued to give Cellectis the power to direct relevant activities of Calyxt and therefore Calyxt continued to be consolidated through the May 31, 2023 consummation of the Merger. On May 31, 2023, Calyxt consummated the Merger, and effective on June 1, 2023, the combined company operates under the name of Cibus, Inc.

Among other things, as part of the Merger, each share of Calyxt’s common stock existing and outstanding immediately prior to the Merger remained outstanding as a share of Class A Common Stock, without any conversion or exchange thereof, and Calyxt issued approximately 16,527,484 shares of Class A Common Stock to unitholders of Cibus Global based on an exchange ratio set forth in the Merger Agreement. Cellectis’ equity interest in Cibus was reduced to 2.9% after the closing of the Merger, which resulted in Cellectis losing control of Cibus.

The Group considers that Cellectis no longer has control of Calyxt as from June 1, 2023. Consequently, Calyxt was deconsolidated on June 1, 2023. Calyxt’s results are included in the Group’s results until May 31, 2023, and continue to be presented as the results of discontinued operations until that date.

On the date of deconsolidation, we derecognized Calyxt’s assets and liabilities and any non-controlling interests in Calyxt at their carrying amount. We recognized the investment retained in Calyxt at its fair value at the date when control was lost. We also reclassified to profit or loss the amounts recognized in other comprehensive income related to Calyxt that should be reclassified according to relevant IFRSs.

On the date of loss of control, the summary impact of Calyxt’s deconsolidation on the Group’s Financial Statements is as follows:


	As of May 31,
	2023
Assets held for sale		(19,714	)
Liabilities related to assets held for sale		21,980
Non-controlling interests		4,440
Net assets, liabilities and equity derecognized		6,706
Consideration received in cash		—
Fair value of the retained investment		15,097
Consideration received		15,097
Profit from deconsolidation		21,803

Pursuant to the deconsolidation of Calyxt, our investment in Calyxt was classified as a non-current financial asset and measured at fair value as of June 30, 2023.

Non-controlling interests

Non-controlling shareholders held a 50.9% interest in Calyxt as of December 31, 2022 and a 52.0% interest in Calyxt as of May 31, 2023. These non-controlling interests were generated during the initial public offering of Calyxt, subsequent follow-on offerings and Calyxt’s at-the-market (ATM) offering program, as well as through vesting and exercises of equity awards.

On June 1, 2023, as Calyxt was deconsolidated and as a result, we derecognized non-controlling interests in Calyxt.

Since June 1, 2023, there are no longer minority interests as the Group holds a 100% interest in all fully consolidated entities.

Property, plant and equipment (Tables)

6 Months Ended

Jun. 30, 2023

Details of Property, Plant and Equipment


	Lands and Buildings			Technical equipment			Fixtures, fittings and other equipment			Assets under construction			Total
	$ in thousands
Net book value as of January 1, 2022		14,733			58,072			3,109			2,932			78,846
Additions to tangible assets		78			(23	)		96			793			945
Disposal of tangible assets		—			54			(143	)		—			(90	)
Reclassification		78			1,254			8			(1,362	)		(23	)
Depreciation expense		(571	)		(2,139	)		(117	)		—			(2,827	)
Translation adjustments		(212	)		(71	)		(19	)		(25	)		(327	)
Net book value as of June 30, 2022		14,106			57,146			2,933			2,338			76,523
Gross value at end of period		22,227			76,379			5,012			2,338			105,955
Accumulated depreciation and impairment at end of period		(8,121	)		(19,233	)		(2,078	)		(0	)		(29,432	)
Net book value as of January 1, 2023		9,321			51,072			2,277			952			63,621
Additions to tangible assets		—			15			11			529			556
Disposal of tangible assets		(172	)		(152	)		(1	)		—			(326	)
Reclassification		290			81			(0	)		(372	)		(1	)
Depreciation expense		(948	)		(3,570	)		(354	)		—			(4,872	)
Translation adjustments		171			51			12			18			252
Net book value as of June 30, 2023		8,661			47,497			1,946			1,127			59,231
Gross value at end of period		18,193			73,035			4,963			1,127			97,318
Accumulated depreciation and impairment at end of period		(9,532	)		(25,537	)		(3,018	)		—			(38,087	)

Current Financial Assets and Cash and Cash Equivalents - Summary of Current Financial Assets and Cash and Cash Equivalents (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Disclosure of current financial assets and cash and cash equivalents [line items]
Current financial assets	$ 1,120	$ 7,907
Cash and cash equivalents	84,386	89,789
Carrying Value [member]
Disclosure of current financial assets and cash and cash equivalents [line items]
Current financial assets	1,120	7,907
Cash and cash equivalents	84,386	89,789
Current financial assets and cash and cash equivalents	85,505	97,696
Estimated Fair Value [member]
Disclosure of current financial assets and cash and cash equivalents [line items]
Current financial assets	1,120	7,907
Cash and cash equivalents	84,386	89,789
Current financial assets and cash and cash equivalents	$ 85,505	$ 97,696

Provisions

6 Months Ended

Jun. 30, 2023

Schedule Of Cash Flow Statement Of Discontinued Operations [Line Items]

Provisions

Note 18. Provisions


	December 31, 2022		Additions		Amounts used during the period		Reversals		OCI		June 30, 2023
	$ in thousands
Pension		2,390		163		—		—		88		2,641
Employee litigation and severance		234		50		—		—		4		288
Commercial litigation		243		491		—		—		7		741
Total		2,867		704		—		—		100		3,671
Non-current provisions		2,390		163		—		—		88		2,641
Current provisions		477		541		—		—		11		1,029

During the six-month period ended June 30, 2023, additions mainly relate to a commercial litigation for $0.5 million with a law office.

Provisions - Summary of Provisions for Termination Benefits (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2023 USD ($)
Disclosure of other provisions [line items]
Beginning balance	$ 2,867
Additions	704
Amounts used during the period	0
Reversals	0
OCI	100
Ending balance	3,671
Non current provisions beginning balance	2,390
Non current provisions additions	163
Non current provisions Amounts used during period	0
Non current provisions Reversals	0
Non current provisions OCI	88
Non current provisions Ending balance	2,641
Current provisions beginning balance	477
Current provisions additions	541
Current provisions Amounts used during period	0
Current provisions Reversals	0
Current provisions OCI	11
Current provisions Ending balance	1,029
Employee litigation and severance, Beginning balance	234
Employee litigation and severance, Additions	50
Employee litigation and severance, Amounts used during the period	0
Employee litigation and severance, Reversals	0
Employee litigation and severance, OCI	4
Employee litigation and severance, Ending balance	288
Commercial litigation [member]
Disclosure of other provisions [line items]
Commercial litigation, Beginning balance	243
Commercial litigation, Additions	491
Commercial litigation, Amounts used during the period	0
Commercial litigation, Reversals	0
Commercial litigation, OCI	7
Commercial litigation, Ending balance	741
Pension [member]
Disclosure of other provisions [line items]
Beginning balance	2,390
Pension, Additions	163
Pension, Amounts used during the period	0
Pension, Reversals	0
OCI	88
Ending balance	$ 2,641

Condensed Consolidated Statements of Financial Position - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Non-current assets
Intangible assets	$ 695	$ 718
Property, plant, and equipment	59,231	63,621
Right-of-use assets	41,457	44,275
Non-current financial assets	13,006	8,791
Total non-current assets	114,389	117,406
Current assets
Trade receivables	422	772
Subsidies receivables	19,488	14,496
Other current assets	7,869	9,078
Current financial assets	1,120	7,907
Cash and cash equivalents	84,386	89,789
Total current assets	113,285	122,043
Total assets held for sale	0	21,768
TOTAL ASSETS	227,674	261,216
Shareholders' equity
Share capital	3,491	2,955
Premiums related to the share capital	476,224	583,122
Currency translation adjustment	(37,050)	(28,605)
Retained earnings	(305,392)	(333,365)
Net income (loss)	(40,715)	(106,139)
Total shareholders' equity - Group Share	96,558	117,968
Non-controlling interests	0	7,973
Total shareholders' equity	96,558	125,941
Non-current liabilities
Non-current financial liabilities	40,270	20,531
Non-current lease debts	46,157	49,358
Non-current provisions	2,641	2,390
Total non-current liabilities	89,068	72,279
Current liabilities
Current financial liabilities	5,185	5,088
Current lease debts	8,270	7,872
Trade payables	19,229	21,456
Deferred revenues and contract liabilities	241	59
Current provisions	1,029	477
Other current liabilities	8,093	13,179
Total current liabilities	42,047	48,131
Total liabilities related to asset held for sale	0	14,864
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 227,674	$ 261,216

Discontinued operations

6 Months Ended

Jun. 30, 2023

Discontinued Operations [Abstract]

Discontinued operations

Note 5. Discontinued operations

Accounting policies

Non-current assets held for sale and disposal groups

In accordance with IFRS 5 Non-current Assets Held for Sale and Discontinued Operations, non-current assets (including property, plant and equipment and intangible assets) and disposal groups (a group of assets to be disposed of) are classified as held for sale if their carrying amount will be recovered principally through a sale transaction and when the following conditions are met: i) management is committed to a plan to sell; ii) the asset or disposal group is available for immediate sale; iii) an active program to locate a buyer is initiated; iv) the sale is highly probably, within 12 months of classification as held for sale; v) the asset or disposal group is being actively marketed for sale at a sales price reasonable in relation to its fair value; and vi) actions required to complete the plan indicate that it is unlikely that plan will be significantly changed or withdrawn.

Non-current assets and disposal groups classified as held for sale are measured at the lower of their carrying amount and fair value less costs to sell, as appropriate.

Depreciation and amortization on these assets cease when they meet the criteria to be classified as non-current assets held for sale.

Non-current assets and related liabilities classified as held for sale are presented separately and are considered as current items in the statement of consolidated financial position.

Discontinued operations

The Group classifies as discontinued operations a component of the Group that either has been disposed of, or is classified as held for sale, and i) represents a separate major line of business or geographical area of operations; ii) is part of a single coordinated plan to dispose of a separate major line of business or geographical area of operations; or iii) is a subsidiary acquired exclusively with a view to resell.

The components of profit or loss after taxes from discontinued operations and the post-tax gain or loss recognized on the measurement to fair value less costs to sell or on the disposal of the assets or disposal groups constituting the discontinued operation would be presented as a single line item in the statement of consolidated comprehensive income.

Cash flows generated by the assets or disposal groups constituting the discontinued operation are presented as a single line item within each of the categories of cash flows in the statement of consolidated cash flows.

Details of discontinued operations and disposal groups

On November 23, 2022, Calyxt received a non-binding letter of intent from Cibus Global regarding a potential reverse merger with Calyxt (with Calyxt absorbing Cibus Global). On January 13, 2023, Calyxt, Calypso Merger Subsidiary, LLC, a wholly-owned subsidiary of Calyxt, Cibus Global and certain other parties, entered into the Merger Agreement with respect to the Merger. In connection with the Merger Agreement, Cellectis executed a voting agreement with Cibus Global to vote in favor of and approve all the transactions contemplated by the Merger Agreement, subject to the terms and conditions thereof.

On May 31, 2023, Calyxt consummated the Merger, and effective on June 1, 2023, the combined company operates under the name Cibus, Inc. Consequently, Cellectis S.A. owned 2.9% of the equity interests of the merged combined company, resulting in a loss of control by the Group over Calyxt. The combined company operates under the name of Cibus, Inc. Cellectis S.A. owned 479,264 shares out of Calyxt’s total outstanding shares of 997,745 shares immediately prior to the Merger (in each case, after giving effect to Calyxt’s 1-for-10 reverse stock split, which became effective on April 24, 2023, and Calyxt’s 1-for-5 reverse stock split, which became effective on May 31, 2023). Among other things, as part of the Merger, each share of Calyxt’s common stock existing and outstanding immediately prior to the Merger remained outstanding as a share of Class A Common Stock, without any conversion or exchange thereof, and Calyxt issued approximately 16,527,484 shares of Class A Common Stock to unitholders of Cibus Global based on an exchange ratio set forth in the Merger Agreement.

The Group considers that Calyxt met the definition of a group of assets held for sale as the criteria defined by IFRS 5 were met on November 23, 2022 and until the loss of control and deconsolidation on May 31, 2023. In the present financial statements, Calyxt is therefore classified as a disposal group held for sale in December 31, 2022 and as a discontinued operation for the six months period ended June 30, 2022 and for the five year period ended May 31, 2023. All tables referring to the six-month period ended June 30, 2023 present Calyxt’s results over a five-month period from January 1, 2023 to May 31, 2023

As prescribed by IFRS 5, Calyxt’s assets and liabilities are measured at the lower of their carrying amount and their fair value less costs to sell from November 23, 2022 and until derecognition on June 1, 2023. No gain or loss was recognized pursuant to this measurement.

The results of Calyxt are as follows :


	For the six-month period ended June 30,
	2022			2023 **
Revenues and other income		73			43
Operating expenses		(12,856	)		(7,113	)
Operating income (loss)		(12,783	)		(7,070	)
Net Financial gain (loss)		5,900			(3,307	)
Net income (loss) from discontinued operations		(6,883	)		(10,377	)

** Figures for the six-month period ended June 30, 2023 include Calyxt’s results over a five-month period from January 1, 2023 to May 31, 2023

The earning per share attributable to Calyxt is as follows :


	For the six-month period ended June 30,
	2022			2023 **
Basic net income (loss) attributable to shareholders of Cellectis per share ($ /share) from discontinued operations		(0.08	)		(0.09	)
Diluted net income (loss) attributable to shareholders of Cellectis per share ($ /share) from discontinued operations		(0.08	)		(0.09	)

** Figures for the six-month period ended June 30, 2023 include Calyxt’s results over a five-month period from January 1, 2023 to May 31, 2023

The net cash flows attributable to Calyxt are as follows:


	For the six-month period ended June 30,
	2022			2023 **
Net cash flows provided by (used in) operating activities of discontinued operations		(11,970	)		(3,644	)
Net cash flows provided by (used in) investing activities of discontinued operations		(744	)		76
Net cash flows provided by (used in) financing activities of discontinued operations		10,207			1,781
(Decrease) increase in cash and cash equivalents		(2,506	)		(1,787	)

** Figures for the six-month period ended June 30, 2023 include Calyxt’s results over a five-month period from January 1, 2023 to May 31, 2023

The major classes of assets and liabilities of Calyxt classified as held for sale are as follows:


	As of December 31,		As of May 31,			As of June 30,
	2022		2023 **			2023
Intangible assets		697		697			—
Property, plant, and equipment		4,110		4,118			—
Right-of-use assets		13,263		13,139			—
Other non-current assets		—		—			—
Other current assets		272		119			—
Cash and cash equivalents		3,427		1,642			—
Total assets held for sale		21,768		19,714			—
Non-current lease debts		13,387		13,140			—
Other non-current liabilities		—		—			—
Current financial liabilities		267		5,647			—
Current lease debts		463		406			—
Trade payables		747		2,567			—
Other current liabilities		—		220			—
Total liabilities related to assets held for sale		14,864		21,980			—
Net assets held for sale		6,903		(2,266	)		—

Discontinued Operations - Schedule Of Cash Flow Statement Of Discontinued Operations (Detail) - USD ($)
$ in Thousands

6 Months Ended

Jun. 30, 2023

Jun. 30, 2022

Net cash flows provided by (used in) operating activities of discontinued operations

$ (3,644)

$ (11,970)

^[1]

Net cash flows provided by (used in) investing activities of discontinued operations

(744)

^[1]

Net cash flows provided by (used in) financing activities of discontinued operations

1,781

10,207

^[1]

Schedule Of Cash Flow Statement Of Discontinued Operations [Line Items]

Net cash flows provided by (used in) operating activities of discontinued operations

(3,644)

^[2]

(11,970)

Net cash flows provided by (used in) investing activities of discontinued operations

^[2]

(744)

Net cash flows provided by (used in) financing activities of discontinued operations

1,781

^[2]

10,207

(Decrease) increase in cash and cash equivalents

$ (1,787)

^[2]

$ (2,506)

[1]	These amounts reflect adjustments made in connection with the presentation of the discontinued operation (Note 5)
[2]	Figures for the six-month period ended June 30, 2023 include Calyxt’s results over a five-month period from January 1, 2023 to May 31, 2023

Current financial assets and Cash and cash equivalents

6 Months Ended

Jun. 30, 2023

Current financial assets and Cash and cash equivalents

Note 11. Current financial assets and Cash and cash equivalents


As of December 31, 2022	Carrying amount		Unrealized Gains/(Losses)		Estimated fair value
			$ in thousands
Current financial assets		7,907		—		7,907
Cash and cash equivalents		89,789		—		89,789
Current financial assets and cash and cash equivalents		97,696		—		97,696


As of June 30, 2023	Carrying amount		Unrealized Gains/(Losses)		Estimated fair value
			$ in thousands
Current financial assets		1,120		—		1,120
Cash and cash equivalents		84,386		—		84,386
Current financial assets and cash and cash equivalents		85,505		—		85,505

11.1 Current financial assets

As of June 30, 2023, current financial assets of $1.1 million correspond to Cytovia’s note receivable. There is no short-term restricted cash included in the current financial assets.

As of December 31, 2022, current financial assets corresponded to Cytovia’s convertible note, measured at its fair value of $7.9 million. There was no short-term restricted cash included in the current financial assets. As of December 31, 2022, short-term restricted cash in the form of deposits to secure a Calyxt furniture and equipment sale-leaseback for $0.2 million which was included in assets held for sale.

On February 12, 2021, we entered into a research collaboration and non-exclusive license agreement with Cytovia Therapeutics, Inc.(“Cytovia”) as amended from time to time (the “Cytovia Agreement”) to develop induced Pluripotent Stem Cell (iPSC) iPSC-derived Natural Killer (NK) and CAR-NK cells edited with our TALEN.

Upon initial execution of the Cytovia Agreement, the Company recorded a note receivable and related license revenue of $20 million in respect of the Upfront Collaboration Consideration. Because the Cytovia Conditions were not met by December 31, 2021, the note receivable was converted to an accounts receivable as of December 31, 2021. In April 2022, in connection with Cytovia’s entering into a definitive business combination agreement with a publicly traded Special Purpose Acquisition Company (“SPAC”), we entered into an amendment to the Cytovia Agreement, pursuant to which we received a $20 million convertible note in payment of the Upfront Collaboration Consideration. The terms of the convertible note provided for (i) conversion into common stock of the combined company upon completion of the business combination or, (ii) in certain circumstances, our ability to elect to be paid in cash on or before December 31, 2022. Because the SPAC business combination was abandoned and the conditions of the convertible note were not met, we and Cytovia entered into an amended and restated note which became effective as of December 22, 2022.

The amended and restated convertible note provides for automatic conversion into common stock of Cytovia in the case of certain fundamental transactions pursuant to which Cytovia becomes a public reporting company and for conversion at Cellectis’ option in connection with certain financing transactions, upon a company sale and at final maturity. In each case such conversion is subject to a 9.9% ownership cap, with the balance issuable in the form of pre-funded warrants. Among other changes, the amended and restated convertible note increases the applicable interest rate of the convertible note to 10% per annum, subject to a 10% step up upon the occurrence and continuation of an event of default, provides for the repayment of 50% of the outstanding amount on April 30, 2023 and extends the final maturity date for the repayment of the remaining outstanding amount to June 30, 2023. On April 30, 2023, we signed a further amendment to agree that 100% of the convertible will be due at final maturity on June 30, 2023.

At the maturity date on June 30, 2023, we did not elect to convert the convertible note into shares of Cytovia’s then-outstanding most senior series of preferred stock and therefore the outstanding amount of the note automatically became due and payable in full in cash by Cytovia for $22.4 million, which includes the $20.0 million principal and $2.4 million of accrued and unpaid interest accrued since the convertible note was issued in April 2022. Cytovia failed to pay this amount, which remains due and payable and Cytovia’s receivable note continues to accrue interest during the continuation of this default, subject to the 10% interest step up. .

The convertible note was classified as a financial asset measured at fair value through profit or loss until June 30, 2023. The fact that Cytovia is in default substantially changes the cash flows associated with this asset, mainly as the convertible note is now only repayable in cash (and no longer subject to conversion into shares of Cytovia). We consider that the criteria for derecognition of this financial asset are met on June 30, 2023, and we therefore derecognized this asset to recognize a new asset, based on such new characteristics.

The new asset is a financial asset payable solely in cash, including principal and interest. We intend to hold this asset until it is repaid by Cytovia. The repayment is already due at initial recognition. This new asset is therefore classified as a current financial asset, initially recognized at its fair value and subsequently measured at amortized cost.

At initial recognition, as this new asset can be analyzed as an originated credit-impaired asset, we included in the estimated fair value of the asset the expected credit losses over the life of the asset.

The expected credit losses have been estimated using both historical and forward-looking estimations, including (i) our ongoing negotiations with Cytovia on the restructuring of [the Cytovia Agreement], and (ii) our assessment of Cytovia’s credit worthiness based on our historical experience with Cytovia and the current financing market for biotechnology companies, and in particular, for companies working on pluripotent stem cells. On the basis of this information, we have prepared recovery scenarios for which the expected loss in each scenario has been weighted by the probability of the scenario occurring.

Considering the expected credit losses over the life of the asset, we have estimated the fair value of Cytovia’s note receivable at the initial recognition date, i.e. June 30, 2023, at $1.1 million. This represents a net loss in fair value of $6.8 million for the six-month period ended June 30, 2023, composed of the impact of the derecognition of the initial asset for $7.9 million and the recognition of the new one for $1.1 million. We recognized this loss in fair value through profit and loss, within financial expenses.


As of June 30, 2023	Fair value in $ thousands
Expected occurrence of most probable scenario +20%		224
Expected occurrence of most probable scenario		1,120
Expected occurrence of most probable scenario -20%		2,015

11.2 Cash and cash equivalents


	As of December 31,		As of June 30,
	2022		2023
	$ in thousands
Cash and bank accounts		65,012		73,520
Money market funds		13,578		-
Fixed bank deposits		11,200		10,866
Total cash and cash equivalents		89,789		84,386

Money market funds earn interest and are refundable overnight. Fixed bank deposits have fixed terms that are less than three months or are readily convertible to a known amount of cash and are subject to an insignificant risk of changes in value.

Property, Plant and Equipment - Additional Information (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	May 31, 2023	Dec. 31, 2022	Jun. 30, 2022	Dec. 31, 2021
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment	$ 59,231		$ 63,621	$ 76,523	$ 78,846
Technical Equipments [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment	47,497		51,072	$ 57,146	$ 58,072
Calyxt [member]
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment	$ 0	$ 4,118	$ 4,110

Other current liabilities (Tables)

6 Months Ended

Jun. 30, 2023

Summary of Other Current Liabilities


	As of December 31,		As of June 30,
	2022		2023
	$ in thousands
VAT Payables		3,058		-
Accruals for personnel related expenses		9,421		7,126
Other		700		967
Total		13,179		8,093

Property, plant and equipment

6 Months Ended

Jun. 30, 2023

Property, plant and equipment

Note 8. Property, plant and equipment


	Lands and Buildings			Technical equipment			Fixtures, fittings and other equipment			Assets under construction			Total
	$ in thousands
Net book value as of January 1, 2022		14,733			58,072			3,109			2,932			78,846
Additions to tangible assets		78			(23	)		96			793			945
Disposal of tangible assets		—			54			(143	)		—			(90	)
Reclassification		78			1,254			8			(1,362	)		(23	)
Depreciation expense		(571	)		(2,139	)		(117	)		—			(2,827	)
Translation adjustments		(212	)		(71	)		(19	)		(25	)		(327	)
Net book value as of June 30, 2022		14,106			57,146			2,933			2,338			76,523
Gross value at end of period		22,227			76,379			5,012			2,338			105,955
Accumulated depreciation and impairment at end of period		(8,121	)		(19,233	)		(2,078	)		(0	)		(29,432	)
Net book value as of January 1, 2023		9,321			51,072			2,277			952			63,621
Additions to tangible assets		—			15			11			529			556
Disposal of tangible assets		(172	)		(152	)		(1	)		—			(326	)
Reclassification		290			81			(0	)		(372	)		(1	)
Depreciation expense		(948	)		(3,570	)		(354	)		—			(4,872	)
Translation adjustments		171			51			12			18			252
Net book value as of June 30, 2023		8,661			47,497			1,946			1,127			59,231
Gross value at end of period		18,193			73,035			4,963			1,127			97,318
Accumulated depreciation and impairment at end of period		(9,532	)		(25,537	)		(3,018	)		—			(38,087	)

Impairment Tests - Additional Information (Detail)	1 Months Ended	6 Months Ended
Impairment Tests - Additional Information (Detail)	Jun. 30, 2023 SegmentUnit	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)
Disclosure of impairment loss and reversal of impairment loss [abstract]
Impairment of assets \| $		$ 0	$ 0
Number of cash generating unit \| SegmentUnit	1

Current Financial Assets and Cash and Cash Equivalents - Summary of Cash and Cash Equivalents (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Cash and cash equivalents [abstract]
Cash and bank accounts	$ 73,520	$ 65,012
Money market funds	0	13,578
Fixed bank deposits	10,866	11,200
Total cash and cash equivalents	$ 84,386	$ 89,789

Trade Receivables and Other Current Assets - Disclosure of Trade Receivables (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Trade and other receivables [abstract]
Trade receivables	$ 422	$ 772
Total net value of trade receivables	$ 422	$ 772

Financial liabilities

6 Months Ended

Jun. 30, 2023

Financial liabilities

Note 12. Financial liabilities

12.1 Detail of financial liabilities


	As of December 31,		As of June 30,
	2022		2023
	$ in thousands
Conditional advances		—		417
Lease debts		49,358		46,157
State Guaranteed loan « PGE »		13,569		11,314
EIB loan		—		16,654
EIB warrants		—		4,875
Other non-current financial liabilities		6,962		7,010
Total non-current financial liabilities and non-current lease debts		69,889		86,427
Lease debts		7,872		8,270
State Guaranteed loan « PGE »		4,972		5,064
Other current financial liabilities		116		122
Total current financial liabilities and current lease debts		12,960		13,455
Trade payables		21,456		19,229
Other current liabilities		13,179		8,093
Total Financial liabilities		117,484		127,204

As of December 31, 2022 and as of June 30, 2023, the other non-current financial liabilities are composed of a $1.1 million loan to finance leasehold improvements in our premises in New York and a Research Tax Credit financing with BPI that was finalized in June 2022 with €5.5 million received representing a non-current financial liability of $5.9 million.

State Guaranteed loan

State Guaranteed Loan (“Prêt Garanti par l’Etat”, or “PGE”) corresponds to Cellectis’ obtention of an €18.5 million (or $20.1 million using exchange rate as of June 30, 2023) loan from a bank syndicate formed with HSBC, Société Générale, Banque Palatine and Bpifrance in the form of a PGE. Initiated by the French Government to support companies during the COVID-19 crisis, the PGE is a bank loan with a fixed interest rate ranging from 0.31% to 3.35%. After an initial interest-only term of two years, the loan is amortized over up to four years at the option of the Company. The French government guarantees 90% of the borrowed amount. As of June 30, 2023, the current liability related to the State Guaranteed loan amounts to $5.1 million and the non-current liability amounts to $11.3 million.

Conditional advances

On March 8, 2023, we signed a grant and refundable advance agreement with BPI to partially support one of our R&D programs which corresponds to UCART 20x22 and related CMC activities. Pursuant to this agreement, on June 19, 2023, we received $0.9 million as the first installment of the refundable advance.

Repayment of this advance is due over a period of 3 years starting on March 31, 2028. The amount to be repaid is equal to the principal adjusted upwards by a discounting effect at an annual rate of 3.04%, in accordance with the European Commission’s principle for State aid. The amount of this discounting adjustment is expected to be $0.2 million and the total amount to be repaid $1.0 million.

The refundable advance from BPI can be analyzed as a government loan as defined by IAS 20. Because his loan bears a lower-than-market interest rate, we measure the fair value of the loan using a market interest rate and recognize the difference with the cash received as a grant. Based on a market rate of 16.1% determined using the credit spread observed for loans

contracted by Cellectis over a comparable term, we measured the fair value of this loan at $0.4 million, resulting in a grant of $0.5 million. The loan is subsequently measured at amortized cost.

European Investment Bank (“EIB”) loan

On December 28, 2022, we entered into a finance contract (the “Finance Contract”) with the EIB for up to €40.0 million in loans to support our research and development activities to advance our pipeline of gene-edited allogeneic cell therapy candidate products for oncology indications (the “R&D Activities”). The Finance Contract provides for funding in three tranches, as follows: (i) an initial tranche of €20.0 million (“Tranche A”); (ii) a second tranche of €15.0 million (“Tranche B”); and (iii) a third tranche of €5.0 million (“Tranche C,” and each of Tranche A, Tranche B, and Tranche C, a “Tranche”), each issuable only in full. Each of our material subsidiaries guarantees our obligations under the Finance Contract. On March 30, 2023, the Company and EIB entered into a Subscription Agreement for Warrants to be Issued by Cellectis S.A. (the “Warrant Agreement”), as required by the Finance Contract.

On April 4, 2023, Cellectis announced the drawdown of the €20 million Tranche A. The disbursement of Tranche A was subject to, among other conditions, (i) the issuance of a specified number of warrants to the benefit of EIB (the “Tranche A Warrants”) and (ii) the completion of certain clinical development milestone by a Cellectis’ licensee, and, as of April 4, 2023, each of (i) and (ii) had been satisfied.

On March 28, 2023, the Company issued 2,779,188 Tranche A Warrants to EIB, in accordance with the terms of the 11th resolution of the shareholders’ meeting held on June 28, 2022 and articles L. 228-91 and seq. of the French Commercial Code, representing 5.0% of the Company’s outstanding share capital as at their issuance date. The exercise price of the Tranche A Warrants is equal to €1.92, corresponding to 99% of the volume-weighted average price per share of the Company’s ordinary shares over the last 3 trading days preceding their issuance. Tranche A will mature six years from its disbursement date. Interest on Tranche A shall be paid in kind, shall be capitalized annually by increasing the principal amount of Tranche A, and shall accrue at a rate equal to 8% per annum. The EIB proceeded to the payment of the €20 million on April 17, 2023.

Each EIB Warrant will entitle EIB to one ordinary share of the Company in exchange for the exercise price (subject to applicable adjustments and anti-dilution provisions). The EIB Warrants will have an exercise price per share equal to 99% of the weighted average price per share of the Company over the last three trading days prior to their issuance. The EIB Warrants with respect to Tranche B and Tranche C are only issuable if the Company elects to drawdown such tranches.

The EIB Warrants expire on the twentieth anniversary of their issuance date, at which time such unexercised EIB Warrants will be automatically deemed null and void. Any outstanding EIB Warrant will become exercisable following the earliest to occur of (i) a change of control event, (ii) the maturity date of Tranche A, (iii) a public take-over bid approved by the Company’s board of directors, (iv) a sale of all or substantially all of certain assets of Cellectis and its subsidiaries, (v) a debt repayment event (i.e. any mandatory repayment pursuant to the Finance Contract or any voluntary payment more than 75% of any Tranche) in respect of one or more Tranches, , or (vi) the receipt of a written demand for repayment from EIB in connection with an event of default under the Finance Agreement (each an “Exercise Event”).

Following any Exercise Event and until expiration of the applicable EIB Warrants, EIB may exercise a put option by which EIB may require the Company to repurchase all or part of the then-exercisable but not yet exercised EIB Warrants. The exercise of such put option would be at the fair market value of the EIB Warrants, subject to a cap equal to the aggregate principal amount disbursed by EIB pursuant to the Finance Contract at the time of the put option, reduced by certain repaid amounts, at the time of exercise of the put option.

Furthermore, in the case of any public take-over bid from a third party or a sale of all outstanding shares of the Company to any person or group of persons acting in concert, the Company shall, subject to certain conditions including the sale by certain shareholders of all of their shares and other securities, be entitled to repurchase all, but not less than all, of the EIB Warrants, at a price equal to the greater of (a) 0.3 times the amount disbursed by the EIB under the Finance Contract divided by the aggregate number of EIB Warrants issued (reduced by the number of exercised EIB Warrants), and (b) the fair market value of the EIB Warrants.

The Company has a right of first refusal to repurchase the EIB Warrants that are offered for sale to a third party under the same terms and conditions of such third party’s offer, provided that such right of first refusal does not apply if the contemplated sale occurs within the scope of a public take-over bid by a third party.

The contract constituted of the loan agreement and the warrants agreement is a hybrid contract, as it contains a non-derivative component (the loan) and derivative options-based components (the warrants and attached options). The loan can be qualified

as the host contract and the warrants and attached options as embedded derivatives. Given, the economic characteristics and specific risks of the embedded derivatives, we consider they should be accounted for separately from the host contract.

The €20.0 million Tranche A loan is classified as a financial liability measured at amortized cost. At initial recognition, i.e. on April 17, 2023, the fair value of this loan include $0.3 million of transaction costs and the $5.2 million fair value of the warrants (see below Derivative Instruments) as the warrants are part of the consideration given to EIB. The initial fair value of the loan is $16.2 million. The loan is subsequently measured at amortized cost, the effective interest rate of the loan being 13.4%

Derivative Instruments – EIB Warrants

The tranche A Warrants issued in favor of the EIB in relation to the Tranche A disbursement in the form of 2,779,188 Bons de Souscription d’Actions (“BSA”) are derivative instruments.

Because of its terms and conditions of the EIB’s put option, we consider that the put option and the tranche A Warrants are to be treated as a single compound embedded derivative.

Because of its terms and conditions, we consider it highly unlikely that the Company will exercise the call option. Accordingly, the call option has been valued at zero and is not accounted for.

The “fixed for fixed” rule of IAS 32, which states that derivatives shall be classified as equity if they can only be settled by the delivery of a fixed number of shares in exchange for a fixed amount of cash or another financial asset, is not met because there is a settlement option that may result in the exchange of a variable number of shares for a variable price in the case of a put option exercise.

As they are not equity instruments, the tranche A Warrants and attached put option are to be classified as a financial liability and will be measured at fair value through profit and loss.

The fair value of the tranche A Warrants and put option has been estimated using a Longstaff Schwartz approach.

This approach is most appropriate to estimate the value of American options (which may be exercised any time from an exercise event until maturity) with complex exercise terms (EIB can exercise the tranche A warrants on the basis of Cellectis’ spot share price or exercise the put option on the basis of the average price of the shares over 90 days).

The Longstaff Schwartz approach is also based on the value of the underlying share price at the valuation date, the observed volatility of the company’s historical share price and the contractual life of the instruments.

The assumptions and results of the warrants valuation are detailed in the following tables:


		Warrants Tranche A
Grant date *		4/17/2023
Expiration date		4/17/2043
Number of options granted		2,779,188
Share entitlement per option		1
Exercise price (in euros per option)		1.92
Valuation method		Longstaff Schwartz

* The grant date retained is the disbursement date of the Tranche A as this is the issuance date defined in the contract.


	Warrants Tranche A
	4/17/2023			6/30/2023
Number of warrants granted	2,779,188			2,779,188
Share price (in euros)	1.87			1.77
Average life of options (in years)	20			19.8
Expected volatility	81.3%				70.6	%
Put option cap (in € thousands)	7.196			7.196
Discount rate	2.85%			2.71%
Expected dividends		0	%		0	%
Fair value per options (in euros per share)	1.73			1.61
Fair value in $ thousands		5,224			4,875

We conducted sensitivity analysis on the expected volatility. As shown in the tables below, the sensitivity of the fair value to the expected volatility is not significant:


As of April 17, 2023	Fair value in $ thousands
Expected volatility -5%		5,206
Expected volatility		5,224
Expected volatility +5%		5,231


As of June 30, 2023	Fair value in $ thousands
Expected volatility -5%		4,790
Expected volatility		4,875
Expected volatility +5%		4,925

12.2 Due dates of the financial liabilities


Balance as of June 30, 2023	Book value		Less than One Year		One to Five Years		More than Five Years
	$ in thousands
Lease debts		54,427		8,270		28,661		17,496
Financial liabilities		45,455		5,185		17,886		22,384
Financial liabilities		99,882		13,455		46,547		39,879
Trade payables		19,229		19,229		—		—
Other current liabilities		8,093		8,093		—		—
Total financial liabilities		127,204		40,777		46,547		39,879

Non-cash stock-based compensation - Summary of assumptions Vesting Details (Detail) - Equity awards [member] - € / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Disclosure of terms and conditions of share-based payment arrangement [line items]
Weighted-Average fair values of stock options granted	€ 1.65	€ 1.31
Share entitlement per options	1	1
Vesting conditions	Performance or Service	Performance or Service
Vesting period	Graded	Graded
Bottom of Range [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Risk-free interest rate	2.45%	0.00%
Exercise price	€ 1.74	€ 2.09
Grant date share fair value	€ 1.7	€ 1.91
Expected volatility	63.70%	58.70%
Expected term (in years)	6.03	6.03
Top of Range [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Risk-free interest rate	2.75%	2.49%
Exercise price	€ 3.17	€ 7.22
Grant date share fair value	€ 3.09	€ 6.74
Expected volatility	64.40%	62.50%
Expected term (in years)	6.15	6.15

Commitments (Tables)

6 Months Ended

Jun. 30, 2023

Details of commitments


As of June 30, 2023	Total		Less than 1 year		1 - 3 years		3 - 5 years		More than 5 years
	$ in thousands
License and collaboration agreements		14,605		1,450		2,900		2,900		7,355
Clinical & Research and Development agreements		70		70		—		—		—
IT licensing agreements		525		525		—		—		—
Total commitments		15,200		2,045		2,900		2,900		7,355

Share capital and premium related to the share capitals - Additional Information (Detail) - USD ($) $ in Thousands		3 Months Ended	6 Months Ended
	Jun. 27, 2023	Dec. 31, 2022	Jun. 30, 2023
Capital structure [line items]
Increase (decrease) through transfer between retained earnings into share premium	$ 134,000
Share premium [member]
Capital structure [line items]
Transaction costs			$ 1,455
Increase (decrease) through transfer between retained earnings into share premium	$ (134,000)
Capital Evolution 2023 [Member]
Capital structure [line items]
Number of shares issued			9,907,800
Gross proceeds			$ 24,800
Transaction costs		$ 600	$ 2,000

Financial Assets and Liabilities - Summary of Financial Assets and Liabilities (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Disclosure of financial assets and liabilities [line items]
Book value on the statement of financial position	$ 127,204	$ 117,484

Disclosure of analysis of single amount of discontinued operations [line items]

The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity’s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity’s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity’s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity’s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity’s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity’s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]

+ References + Details

Accounting Principles - Additional Information (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Disclosure of changes in accounting estimates [abstract]
Cash and cash equivalents	$ 84,386	$ 89,789

Scope of Consolidation and Non-Consolidated Entities - Impact of Deconsolidation on Group's Financial Statements (Detail) - USD ($)

3 Months Ended

6 Months Ended

May 31, 2023

Jun. 30, 2023

Jun. 30, 2022

^[1]

Jun. 30, 2023

Jun. 30, 2022

^[2]

Dec. 31, 2022

$ 0

$ 14,864,000

Non-controlling interests

$ 7,973,000

Profit from deconsolidation

$ (5,647,000)

$ (442,000)

$ (10,377,000)

$ (6,883,000)

Calyxt Inc [Member] | Discontinued operations [member]

Disclosure of analysis of single amount of discontinued operations [line items]

Assets held for sale

$ (19,714)

21,980

Non-controlling interests

4,440

Net assets, liabilities and equity derecognized

6,706

Consideration received in cash

Fair value of the retained investment

15,097

Consideration received

15,097

Profit from deconsolidation

$ 21,803

[1]	These amounts reflect adjustments made in connection with the presentation of the discontinued operation (Note 5)
[2]	These amounts reflect adjustments made in connection with the presentation of the discontinued operation (Note 5)

The Company - Additional Information (Detail) - $ / shares		1 Months Ended		12 Months Ended
	Jun. 01, 2023	Jun. 30, 2023	May 31, 2023	Dec. 31, 2022	Jun. 30, 2022	Dec. 31, 2021
Disclosure of subsidiaries [line items]
Ownership interest in subsidiary		100.00%
Par value per share		$ 0.05		$ 0.05	$ 0.05	$ 0.05
Calyxt Inc [Member]
Disclosure of subsidiaries [line items]
Ownership interest in subsidiary	2.90%		48.00%	49.10%
Par value per share			$ 0.0001
Calyxt Inc [Member] \| Class A Common Stock [Member]
Disclosure of subsidiaries [line items]
Par value per share			$ 0.0001
Number of shares issued			16,527,484

Information Concerning the Group's Consolidated Operations - Details of Operating Expenses by Nature (Detail) - USD ($)
$ in Thousands

3 Months Ended

6 Months Ended

Jun. 30, 2023

Jun. 30, 2022

Jun. 30, 2023

Jun. 30, 2022

Cost of good sold

$ 0

^[1]

$ 0

^[2]

Royalty expenses

(55)

(329)

^[1]

(389)

(714)

^[2]

Total research and development expenses

(55)

(329)

^[1],[3]

(389)

(714)

^[2],[4]

(22,144)

(25,630)

^[3]

(43,225)

(52,231)

^[4]

Total selling, general and administrative expenses

(3,950)

(4,830)

^[3]

(8,914)

(10,893)

^[4]

Other operating income (expenses)

490

753

^[1],[3]

(83)

774

^[2],[4]

Research and Development Expenses [member]

Social charges on free shares and stock option grants

Wages and salaries

(8,463)

(10,003)

^[1]

(17,520)

(21,161)

^[2]

(47)

^[1]

(181)

^[2]

Purchases and external expenses

(1,186)

(1,454)

^[1]

(2,289)

(3,134)

^[2]

Personnel expenses

(9,696)

(11,419)

^[1]

(19,990)

(24,263)

^[2]

(8,352)

(9,847)

^[1]

(15,009)

(19,113)

^[2]

Other

(4,097)

(4,364)

^[1]

(8,227)

(8,854)

^[2]

Total research and development expenses

(22,144)

(25,630)

^[1]

(43,225)

(52,231)

^[2]

Selling, General and Administrative Expenses [member]

Social charges on free shares and stock option grants

Wages and salaries

(1,480)

(1,593)

^[1]

(2,983)

(3,226)

^[2]

(7)

^[1]

(81)

(39)

^[2]

Purchases and external expenses

(460)

(557)

^[1]

(977)

(1,193)

^[2]

Personnel expenses

(1,947)

(2,142)

^[1]

(4,041)

(4,458)

^[2]

(1,284)

(2,019)

^[1]

(3,426)

(5,034)

^[2]

Other

(719)

(669)

^[1]

(1,447)

(1,400)

^[2]

Total selling, general and administrative expenses

(3,950)

(4,830)

^[1]

(8,914)

(10,893)

^[2]

Personnel Expenses [member]

Social charges on free shares and stock option grants

Wages and salaries

(9,943)

(11,596)

^[1]

(20,503)

(24,387)

^[2]

(54)

^[1]

(263)

(8)

^[2]

Cash flows from operating activities

(1,646)

(2,011)

^[1]

(3,265)

(4,327)

^[2]

Personnel expenses

$ (11,643)

$ (13,561)

^[1]

$ (24,031)

$ (28,722)

^[2]

[1]	These amounts reflect adjustments made in connection with the presentation of the discontinued operation (Note 5)
[2]	These amounts reflect adjustments made in connection with the presentation of the discontinued operation (Note 5)
[3]	These amounts reflect adjustments made in connection with the presentation of the discontinued operation (Note 5)
[4]	These amounts reflect adjustments made in connection with the presentation of the discontinued operation (Note 5)

Unaudited Interim Statements of Consolidated Cash Flows - USD ($)
$ in Thousands

6 Months Ended

Jun. 30, 2023

Jun. 30, 2022

Net loss for the period of discontinued operations

$ (46,108)

$ (54,211)

^[1],[2]

(10,377)

(6,807)

^[3]

Net (loss) income for the period of continuing operations

(35,730)

(47,404)

^[3]

Adjustment to reconcile net income (loss) to cash provided by (used in) operating activities

Intercompany transactions between continuing and discontinued operations

^[4]

^[3]

Amortization and depreciation

8,875

9,402

^[3]

Net loss (income) on disposals

155

^[3]

Net financial loss (gain)

(11,580)

(9,213)

^[3]

Realized foreign exchange gain (loss)

258

^[3]

3,265

4,327

^[3]

Provisions

671

(113)

^[3]

Other non-cash items

(460)

^[3]

(381)

^[3]

Interest (paid) / received

1,416

^[3]

Operating cash flows before change in working capital

(32,810)

(43,524)

^[3]

Decrease (increase) in trade receivables and other current assets

996

(2,879)

^[3]

Decrease (increase) in subsidies receivables

(4,649)

(2,807)

^[3]

(Decrease) increase in trade payables and other current liabilities

(7,441)

796

^[3]

(Decrease) increase in deferred income

180

202

^[3]

Change in working capital

(10,915)

(4,687)

^[3]

Net cash flows provided by (used in) operating activities of continuing operations

(43,725)

(48,212)

^[3]

Net cash flows provided by (used in) operating activities of discontinued operations

(3,644)

(11,970)

^[3]

Net cash flows provided by (used in) operating activities

(47,369)

(60,181)

^[3]

Cash flows from investment activities

Calyxt's cash and cash equivalents disposed of

^[5]

(1,642)

(0)

^[3]

Acquisition of property, plant and equipment

(483)

(1,541)

^[3]

Net change in non-current financial assets

489

(252)

^[3]

Net cash flows provided by (used in) investing activities of continuing operations

(1,636)

(1,793)

^[3]

Net cash flows provided by (used in) investing activities of discontinued operations

(744)

^[3]

Cash flows provided by (used in) investment activities

(1,558)

(2,537)

^[3]

Cash flows from financing activities

Increase in share capital of Cellectis after deduction of transaction costs

23,561

^[3]

Increase in borrowings

22,507

5,969

^[3]

Decrease in borrowings

(2,547)

^[3]

Interest paid on financial debt

(155)

(176)

^[3]

Payments on lease debts

(5,550)

(5,693)

^[3]

Net cash flows provided by financing activities of continuing operations

37,817

100

^[3]

Net cash flows provided by (used in) financing activities of discontinued operations

1,781

10,207

^[3]

Net cash flows provided by (used in) financing activities

39,597

10,307

^[3]

(Decrease) increase in cash and cash equivalents

(9,329)

(52,411)

^[3]

Cash and cash equivalents at the beginning of the year

93,216

185,636

^[3]

Effect of exchange rate changes on cash

499

(3,785)

^[3]

Cash from discontinued operations

11,316

^[3]

Cash from continuing operations

84,386

118,123

^[3]

Cash and cash equivalents at the end of the period

$ 84,386

$ 129,440

^[3]

[1]	These amounts reflect adjustments made in connection with the presentation of the discontinued operation (Note 5)
[2]	These amounts reflect adjustments made in connection with the presentation of the discontinued operation (Note 5)
[3]	These amounts reflect adjustments made in connection with the presentation of the discontinued operation (Note 5)
[4]	Net cash flows used in operating activities from continuing and discontinued operations being presented separately, the effect of intercompany transactions between the two categories is presented within the cash flows of each, although these transactions are fully eliminated in the Group’s financial statements.
[5]	On the date of loss of control, Calyxt’s cash and cash equivalents were derecognized. For better clarity, this impact is presented in investing activities separately from cash flows from discontinued operations.

Right-of-use assets (Tables)

6 Months Ended

Jun. 30, 2023

Disclosure Of Detailed Information About Breakdown Of Right Of Use Assets Explanatory

The breakdown of right-of-use assets is as follows:


	Building lease			Office and laboratory equipment			Total
	$ in thousands
Net book value as of January 1, 2022		55,197			14,226			69,423
Additions		487			328			816
Depreciation expense		(1,418	)		(1,225	)		(2,642	)
Translation adjustments		(304	)		(64	)		(369	)
Net book value as of June 30, 2022		53,962			13,265			67,227
Gross value at end of period		69,847			19,875			89,721
Accumulated depreciation and impairment at end of period		(15,885	)		(6,609	)		(22,494	)
Net book value as of January 1, 2023		33,666			10,608			44,275
Additions		879			96			975
Disposal of right-of-use asset		(102	)		—			(102	)
Depreciation expense		(2,292	)		(1,685	)		(3,977	)
Translation adjustments		237			49			286
Net book value as of June 30, 2023		32,389			9,068			41,457
Gross value at end of period		50,684			17,932			68,616
Accumulated depreciation at end of period		(18,295	)		(8,864	)		(27,159	)

Scope of consolidation and non-consolidated entities (Tables)

6 Months Ended

Jun. 30, 2023

Discontinued operations [member]

Disclosure of analysis of single amount of discontinued operations [line items]

Impact of Deconsolidation on Group's Financial Statements

On the date of loss of control, the summary impact of Calyxt’s deconsolidation on the Group’s Financial Statements is as follows:


	As of May 31,
	2023
Assets held for sale		(19,714	)
Liabilities related to assets held for sale		21,980
Non-controlling interests		4,440
Net assets, liabilities and equity derecognized		6,706
Consideration received in cash		—
Fair value of the retained investment		15,097
Consideration received		15,097
Profit from deconsolidation		21,803

Deferred revenues and contract liabilities

6 Months Ended

Jun. 30, 2023

Deferred revenues and contract liabilities

Note 14. Deferred revenues and contract liabilities


	As of December 31, 2022		As of June 30, 2023
	$ in thousands
Deferred revenues and contract liabilities		59		241
Total Deferred revenue and contract liabilities		59		241

Deferred revenues and contract liabilities increased by $0.2 million between December 31, 2022 and June 30 2023 related to annual license fee due under the Research Collaboration and Exclusive License Agreement entered into between Cellectis and Iovance Therapeutics, Inc. (“Iovance”) on December 30, 2019 as amended (the “Iovance Agreement”).

Other Current Liabilities - Summary of Other Current Liabilities (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Miscellaneous current liabilities [abstract]
VAT Payables	$ 0	$ 3,058
Accruals for personnel related expenses	7,126	9,421
Other	967	700
Total other current liabilities	$ 8,093	$ 13,179

Information Concerning the Group's Consolidated Operations - Additional Information (Detail)
€ in Millions

3 Months Ended

6 Months Ended

12 Months Ended

Jun. 19, 2023

USD ($)

Jun. 30, 2023

USD ($)

Jun. 30, 2022

USD ($)

Jun. 30, 2023

EUR (€)

Jun. 30, 2023

USD ($)

Jun. 30, 2022

USD ($)

Dec. 31, 2022

USD ($)

May 31, 2023

Consolidated operations [line items]

Increase (decrease) in net foreign exchange gain

$ 3,100,000

$ 900,000

Revenue from performance obligation

1,500,000

Collaboration agreements

$ 998,000

^[1]

$ 2,530,000

^[2]

Decrease /increase in financial income

22,300,000

20,800,000

Increase in financial income attributable to profit from deconsolidation

21,800,000

increase in gain from financial investments

600,000

1,100,000

Net foreign exchange gain

9,216,000

6,146,000

9,248,000

8,310,000

$ 8,300,000

Reclassified from other comprehensive income pursuant to deconsolidation

8,000,000

Loss in financial expenses

3,500,000

6,800,000

Decrease /increase in financial Expenses

14,600,000

18,400,000

Increase in financial expenses attributable to loss in fair value deconsolidation

10,200,000

Net foreign exchange loss

1,289,000

592,000

2,278,000

878,000

$ 900,000

Upfront amount | €

€ 1.0

Change In Fair Value Of Foreign Exchange Loss

3,500,000

6,800

Increase/ Decrease in foreign exchange losses

700,000

1,400,000

Change in fair value of foreign exchange gain

400,000

Decrease In Foreign Exchange Loss

3,600,000

Other revenues from collaboration agreements recognized on licence agreement amendment

$ 1,000,000

1,000,000

$ 1,000,000

Increase (Decrease) In Research Tax Credit

800,000

Decrease in total operating expenses

4,400,000

10,500,000

Decrease in purchases, external expenses and other

2,500,000

6,300,000

Decrease in wages

1,700,000

3,900,000

Decrease in non-cash stock based compensation expense

400,000

1,100,000

Decrease in cost of revenue

300,000

Decrease in other operating income

300,000

900,000

Increase in social charges on stock options grants expense

100,000

300,000

Increase (decrease) in other income

400,000

1,600,000

Proceeds from refundable advance payment

$ 900,000

Recognized grant on fair value of loan

500,000

Contractual grant on loan subsidy

300,000

Recognition of grant the refundable advance

800,000

Fair value of loan

400,000

Grant received on loan

$ 500,000

Increase of interest of loan

$ 400,000

$ 400

Consolidated operations [line items]

Percentage of voting equity interests acquired

48.00%

[1]	These amounts reflect adjustments made in connection with the presentation of the discontinued operation (Note 5)
[2]	These amounts reflect adjustments made in connection with the presentation of the discontinued operation (Note 5)

Information Concerning the Group's Consolidated Operations - Disclosure of Income Tax (Expense or Income) (Detail) - USD ($)
$ in Thousands

3 Months Ended

6 Months Ended

Jun. 30, 2023

Jun. 30, 2022

Jun. 30, 2023

Jun. 30, 2022

Major components of tax expense (income) [abstract]

Effective tax expense

$ (258)

$ 0

^[1]

$ 258

$ 0

^[2]

[1]	These amounts reflect adjustments made in connection with the presentation of the discontinued operation (Note 5)
[2]	These amounts reflect adjustments made in connection with the presentation of the discontinued operation (Note 5)

The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]

+ References + Details

Subsequent events

6 Months Ended

Jun. 30, 2023

Subsequent events

Note 20. Subsequent events

On August 7, 2023, no significant subsequent events have occurred.

Non-cash stock-based compensation - Summary of Number of Shares Outstanding and Weighted Average Grant Date Fair Value (Detail) - S A free shares [member]	6 Months Ended	12 Months Ended
	Jun. 30, 2023 € / shares	Dec. 31, 2022 € / shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Option outstanding, beginning balance	909,113	922,701
Option outstanding, granted	342,900	354,770
Option outstanding, exercised/vested		(191,658)
Option outstanding, forfeited, cancelled or expired	(36,112)	(176,700)
Option outstanding, ending balance	1,215,901	909,113
Weighted average exercise price per share, beginning balance	€ 11.18	€ 14.15
Weighted average exercise price per share, granted	3.08	2.79
Weighted average exercise price per share, exercised		17.96
Weighted average exercise price per share, cancelled, forfeited or expired	11.1	13.99
Weighted average exercise price per share, ending balance	€ 8.9	€ 11.18

Unaudited Condensed Consolidated Statements of Changes in Shareholders' Equity (Parenthetical) - USD ($)

1 Months Ended

6 Months Ended

May 31, 2023

Jun. 30, 2023

Jun. 30, 2022

Proceeds from issuing shares

$ 23,561,000

$ 0

^[1]

Cellectis Follow-on Offering [Member]

American Depository Shares [Member] | Cellectis Follow-on Offering [Member]

Issuance costs

$ 600

Transaction costs

$ 2,000

Number of shares issued

9,907,800

Gross proceeds

$ 24,800

Calyxt Inc [member]

Proportion of ownership interest in subsidiary

48.00%

Derecognition of minority interest

$ 4,400

[1]	These amounts reflect adjustments made in connection with the presentation of the discontinued operation (Note 5)

Non-cash stock-based compensation - Summary of Information on Stock Option Activity (Detail) - Stock options [member]				6 Months Ended	12 Months Ended
	Jun. 26, 2023	May 04, 2023	Jan. 24, 2023	Jun. 30, 2023 € / shares	Dec. 31, 2022 € / shares	Dec. 31, 2021 € / shares
Disclosure Of Number And Weighted Average Exercise Prices Of Share Options and awards [Line Items]
Option exercisable, beginning balance				7,400,519	7,566,679
Option exercisable, ending balance				7,800,007	7,400,519	7,566,679
Weighted- average exercise price per share, beginning balance				€ 24.58	€ 24.78
Weighted- average exercise price per share, granted				0	0
Weighted- average exercise price per share, exercised				0	0
Weighted- average exercise price per share, forfeited or expired				0	0
Weighted- average exercise price per share, ending balance				€ 23.84	€ 24.58	€ 24.78
Option outstanding, beginning balance				8,787,264	9,159,794
Option outstanding, granted	55,690	358,100	1,417,321	1,835,411	828,549
Option outstanding, exercised/vested				0
Option outstanding, forfeited, cancelled or expired				(22,638)	(1,201,079)
Option outstanding, ending balance				10,600,037	8,787,264	9,159,794
Weighted average exercise price per share, beginning balance				€ 22.31	€ 23.5
Weighted average exercise price per share, granted				2.86	4.18
Weighted average exercise price per share, exercised				0
Weighted average exercise price per share, cancelled, forfeited or expired				18.29	18.85
Weighted average exercise price per share, ending balance				€ 18.95	€ 22.31	€ 23.5
Remaining Average Useful Life				5 years 1 month 6 days	4 years 7 months 6 days	5 years 3 months 18 days

Current financial assets and Cash and cash equivalents (Tables)

6 Months Ended

Jun. 30, 2023

Summary of Current Financial Assets and Cash and Cash Equivalents


As of December 31, 2022	Carrying amount		Unrealized Gains/(Losses)		Estimated fair value
			$ in thousands
Current financial assets		7,907		—		7,907
Cash and cash equivalents		89,789		—		89,789
Current financial assets and cash and cash equivalents		97,696		—		97,696


As of June 30, 2023	Carrying amount		Unrealized Gains/(Losses)		Estimated fair value
			$ in thousands
Current financial assets		1,120		—		1,120
Cash and cash equivalents		84,386		—		84,386
Current financial assets and cash and cash equivalents		85,505		—		85,505

Schedule of Fair Value Through Profit and Loss

We recognized this loss in fair value through profit and loss, within financial expenses.


As of June 30, 2023	Fair value in $ thousands
Expected occurrence of most probable scenario +20%		224
Expected occurrence of most probable scenario		1,120
Expected occurrence of most probable scenario -20%		2,015

Details of Cash and Cash Equivalents

Cash and cash equivalents


	As of December 31,		As of June 30,
	2022		2023
	$ in thousands
Cash and bank accounts		65,012		73,520
Money market funds		13,578		-
Fixed bank deposits		11,200		10,866
Total cash and cash equivalents		89,789		84,386

Financial Liabilities - Schedule of Financial Liabilities (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Disclosure of financial liabilities [line items]
Conditional advances	$ 417	$ 0
Lease debts	46,157	49,358
EIB loan	16,654	0
EIB warrants	4,875	0
Other non-current financial liabilities	7,010	6,962
Total non-current financial liabilities and non-current lease debts	86,427	69,889
Lease debts	8,270	7,872
Other current financial liabilities	122	116
Total current financial liabilities and current lease debts	13,455	12,960
Trade payables	19,229	21,456
Other current liabilities	8,093	13,179
Total financial liabilities	127,204	117,484
State Guaranted Loan [Member]
Disclosure of financial liabilities [line items]
State Guaranteed loan PGE	11,314	13,569
State Guaranteed loan « PGE »	$ 5,064	$ 4,972

Trade Receivables and Other Current Assets - Disclosure of Other Current Assets (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Other Current Assets [abstract]
VAT receivables	$ 999	$ 1,140
Prepaid expenses and other prepayments	5,979	6,233
Tax and social receivables	63	1,166
Deferred expenses and other current assets	828	538
Total other current assets	$ 7,869	$ 9,078

Share capital and premium related to the share capitals

6 Months Ended

Jun. 30, 2023

Share capital and premium related to the share capitals

Note 15. Share capital and premium related to the share capitals


Nature of the Transactions	Share Capital		Share premium			Number of shares		Nominal value
	$ in thousands (except number of shares)							in $
Balance as of January 1, 2022		2,945		934,696			45,484,310	0.05
Exercise of share warrants, employee warrants and stock options		1		—			26,500		—
Non-cash stock-based compensation expense		—		5,331			—		—
Other movements		—		(372,744	)		—		—
Balance as of June 30, 2022		2,946		567,284			45,510,810	0.05
Balance as of January 1, 2023		2,955		583,122			45,675,968	0.05
Non-cash stock-based compensation expense		—		4,053			—		—
Capital increase of Cellectis (1)		536		24,482			9,907,800
Transaction costs related to Cellectis’ capital increase (2)		—		(1,455	)		—		—
Other movements		—		(133,976	)		—		—
Balance as of June 30, 2023		3,491		476,224			55,583,768	0.05

Capital evolution during the six-month period ended June 30, 2023

(1)

During the six-month period ended June 30, 2023, 9,907,800 shares were issued in the Cellectis Follow-on Offering with gross proceeds of $24.8 million.

(2)

These costs correspond to the issuance costs incurred in 2023 in connection with the Cellectis Follow-on Offering as a reduction of share premium, in addition to the $0.6 million costs incurred and deducted from Equity in the fourth quarter of 2022. The total transaction costs for this Cellectis Follow-on Offering amount to $2.0 million.

(3)

During the annual shareholders meeting of June 27, 2023, the shareholders, in accordance with French Law, approved the absorption of $134.0 million of retain²ed earnings into share premium. This transaction has no impact on the total equity, comprehensive income (loss), assets (including cash) nor liabilities.

Unaudited Interim Statements of Consolidated Comprehensive Income (Loss) - USD ($)
$ in Thousands

3 Months Ended

6 Months Ended

Jun. 30, 2023

Jun. 30, 2022

Jun. 30, 2023

Jun. 30, 2022

^[2]

Statement of comprehensive income [abstract]

Actuarial gains and losses

$ (13,583)

$ (19,454)

^[1]

$ (46,108)

$ (54,211)

^[3]

(21)

791

^[4]

(42)

1,218

Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss Net Of Tax From Continuing Operations, Total

(21)

791

^[4]

(42)

1,218

Currency translation adjustment

4,751

(15,282)

^[4]

2,272

(20,315)

Other Comprehensive Income That Will Be Reclassified To Profit Or Loss Net Of Tax From Continuing Operations, Total

4,751

(15,282)

^[4]

2,272

(20,315)

Other Comprehensive Income from Discontinued Operations, Total

(4,906)

6,412

^[4]

(1,233)

8,337

Total Comprehensive income (loss)

(13,760)

(27,533)

^[4]

(45,111)

(64,971)

Attributable to shareholders of Cellectis

(11,139)

(26,522)

^[4]

(41,172)

(61,246)

Attributable to non-controlling interests

$ (2,620)

$ (1,011)

^[4]

$ (3,939)

$ (3,725)

[1]	These amounts reflect adjustments made in connection with the presentation of the discontinued operation (Note 5)
[2]	These amounts reflect adjustments made in connection with the presentation of the discontinued operation (Note 5)
[3]	These amounts reflect adjustments made in connection with the presentation of the discontinued operation (Note 5)
[4]	These amounts reflect adjustments made in connection with the presentation of the discontinued operation (Note 5)

Discontinued Operations - Summary of Assets and Liabilities Held For Sale (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	May 31, 2023	Dec. 31, 2022	Jun. 30, 2022	Dec. 31, 2021
Schedule Of Income Statement Of Discontinued Operations [Line Items]
Intangible assets	$ 695		$ 718
Property, plant, and equipment	59,231		63,621	$ 76,523	$ 78,846
Right-of-use assets	41,457		44,275	$ 67,227	$ 69,423
Other current assets	7,869		9,078
Cash and cash equivalents	84,386		89,789
Non-current lease debts	46,157		49,358
Current financial liabilities	5,185		5,088
Current lease debts	8,270		7,872
Trade payables	19,229		21,456
Other current liabilities	8,093		13,179
Total liabilities related to asset held for sale	0		14,864
Calyxt [member]
Schedule Of Income Statement Of Discontinued Operations [Line Items]
Intangible assets	0	$ 697	697
Property, plant, and equipment	0	4,118	4,110
Right-of-use assets	0	13,139	13,263
Other non-current assets	0	0	0
Other current assets	0	119	272
Cash and cash equivalents	0	1,642	3,427
Total assets held for sale	0	19,714	21,768
Non-current lease debts	0	13,140	13,387
Other non-current liabilities	0	0	0
Current financial liabilities	0	5,647	267
Current lease debts	0	406	463
Trade payables	0	2,567	747
Other current liabilities	0	220	0
Total liabilities related to asset held for sale	0	21,980	14,864
Net assets held for sale	$ 0	$ (2,266)	$ 6,903

Information concerning the Group's Consolidated Operations

6 Months Ended

Jun. 30, 2023

Information concerning the Group's Consolidated Operations

Note 4. Information concerning the Group’s Consolidated Operations

4.1 Revenues and other income

4.1.1 For the six-month period ended June 30

Revenues by country of origin and other income


	For the six-month period ended June 30,
	2022 *		2023
	$ in thousands
From France		2,972		317
From USA		—		—
Revenues		2,972		317
Research tax credit		3,544		4,391
Subsidies and other		7		851
Other income		3,551		5,242
Total revenues and other income		6,523		5,560

* These amounts reflect adjustments made in connection with the presentation of the discontinued operation (Note 5)

The decrease of revenues from France between the six months periods ended June 30, 2022 and 2023 reflects the recognition of two milestones related to Cellectis’ agreement with Cytovia Therapeutics, Inc (“Cytovia”) for $1.5 million and the recognition of $1.0 million related to the change of control of a licensee pursuant to the terms of its license agreement with

Cellectis and the amendment to such license agreement (extension of its option term), each in 2022 while recognition of revenues for the six-month period ended June 30, 2023 is not material.

The increase in other income of $1.6 million between the six months periods ended June 30, 2022 and 2023 reflects an increase of research tax credit of $0.8 million due to an increase of eligible expenses, and the recognition of a $0.8 million income related to the grant and refundable advance agreement signed with Bpifrance (“BPI”) to partially support a R&D program related to Cellectis’ UCART 20x22. We received on June 19, 2023 a $0.9 million refundable advance payment from BPI. This refundable advance is accounted for as a government loan as defined by IAS 20. Because this loan bears a below market interest rate, we measured the fair value of the loan using a market interest rate and recognize as a grant the difference between the cash the cash received and the estimated fair value of the loan. The fair value of the loan on June 19, 2023 was $0.4 million, resulting in a grant of $0.5 million. We recognized this $0.5 million grant in profit and loss of the six-month period ended June 30, 2023, in addition to the $0.3 million contractual grant, as the subsidized expenses have been incurred and the contractual conditions for obtaining the subsidy have been met.

Revenues by nature


	For the six-month period ended June 30,
	2022 *		2023
	$ in thousands
Recognition of previously deferred upfront payments		—		—
Other revenues from collaboration agreements		2,530		—
Collaboration agreements		2,530		—
Licenses		276		264
Products & services		166		53
Total revenues		2,972		317

* These amounts reflect adjustments made in connection with the presentation of the discontinued operation (Note 5)

The Company did not recognize any revenue from collaboration agreements for the six-month period ended June 30, 2023, while recognition of other revenues for the six-month period ended June 30, 2022 mainly reflects (ii) the recognition of two development milestones for an aggregate of $1.5 million in connection with the Research Collaboration and License Agreement entered into between Cellectis and Cytovia on February 21, 2021, as amended from time to time (the “Cytovia Agreement”), and (iii) the recognition of $1.0 million related to the change of control of a licensee pursuant to the terms of its license agreement with Cellectis and the amendment to such license agreement (extension of its option term).

Revenues related to licenses include royalties received under our various license agreements.

4.1.2 For the three-month period ended June 30

Revenues by country of origin and other income


	For the three-month period ended June 30,
	2022 *		2023
	$ in thousands
From France		1,307		178
From USA		—		—
Revenues		1,307		178
Research tax credit		1,416		1,275
Subsidies and other		0		547
Other income		1,416		1,823
Total revenues and other income		2,723		2,001

* These amounts reflect adjustments made in connection with the presentation of the discontinued operation (Note 5)

The Company did not recognize any revenue from collaboration agreements for the three-month period ended June 30, 2023, while recognition of other revenues for the three-month period ended June 30, 2022 mainly reflects recognition of $1.0 million related to the change of control of a licensee pursuant to the terms of its license agreement with Cellectis and the amendment to such license agreement (extension of its option term).

The increase in other income of $0.4 million between the three months periods ended June 30, 2022 and 2023 reflects the recognition of a $0.5 million grant related to the refundable advance received from BPI, as described in note 4.1.1 above.

Revenues by nature


	For the three-month period ended June 30,
	2022 *		2023
	$ in thousands
Recognition of previously deferred upfront payments		—		—
Other revenues from collaboration agreements		998		—
Collaboration agreements		998		—
Licenses		158		157
Products & services		150		22
Total revenues		1,307		178

* These amounts reflect adjustments made in connection with the presentation of the discontinued operation (Note 5)

The company did not recognize any revenue from collaboration agreements for the three-month period ended June 30, 2023, while recognition of other revenues for the three-month period ended June 30, 2022 mainly reflects recognition of $1.0 million related to the change of control of a licensee pursuant to the terms of its license agreement with Cellectis and the amendment to such license agreement (extension of its option term).

Revenues related to licenses include royalties received under our various license agreements.

4.2 Operating expenses

4.2.1 For the six-month period ended June 30


	For the six-month period ended June 30,
Cost of revenue	2022 *			2023

Cost of goods sold		0			—
Royalty expenses		(714	)		(389	)
Cost of revenue		(714	)		(389	)


	For the six-month period ended June 30,
Research and development expenses	2022 *			2023

Wages and salaries		(21,161	)		(17,520	)
Social charges on stock option grants		32			(181	)
Non-cash stock-based compensation expense		(3,134	)		(2,289	)
Personnel expenses		(24,263	)		(19,990	)
Purchases and external expenses		(19,113	)		(15,009	)
Other		(8,854	)		(8,227	)
Total research and development expenses		(52,231	)		(43,225	)


	For the six-month period ended June 30,
Selling, general and administrative expenses	2022 *			2023

Wages and salaries		(3,226	)		(2,983	)
Social charges on stock option grants		(39	)		(81	)
Non-cash stock-based compensation expense		(1,193	)		(977	)
Personnel expenses		(4,458	)		(4,041	)
Purchases and external expenses		(5,034	)		(3,426	)
Other		(1,400	)		(1,447	)
Total selling, general and administrative expenses		(10,893	)		(8,914	)


	For the six-month period ended June 30,
Personnel expenses	2022 *			2023

Wages and salaries		(24,387	)		(20,503	)
Social charges on stock option grants		(8	)		(263	)
Non-cash stock-based compensation expense		(4,327	)		(3,265	)
Total personnel expenses		(28,722	)		(24,031	)


	For the six-month period ended June 30,
	2022 *		2023
Other operating income (expenses)		774		(83	)

* These amounts reflect adjustments made in connection with the presentation of the discontinued operation (Note 5)

The decrease in total operating expenses of $10.5 million from the six-month period ended June 30, 2022 to the six-month period ended June 30, 2023 resulted primarily from (i) a decrease of $6.3 million in purchases, external expenses and other, due to continuing internalization of manufacturing and quality control activities (ii) a decrease of $3.9 million in wages due to headcount reduction, (iii) a decrease of $1.1 million in non-cash stock based compensation expense and (iv) a decrease of $0.3 million in cost of revenues due to the diminution of milestones recognition, partially offset by a (i) a decrease of other operating income of $0.9 million and (ii) a $0.3 million increase in social charges on stock option grants expenses.

4.2.2 For the three-month period ended June 30


	For the three-month period ended June 30,
	2022 *			2023

Cost of goods sold		0			—
Royalty expenses		(329	)		(55	)
Cost of revenue		(329	)		(55	)


	For the three-month period ended June 30,
Research and development expenses	2022 *			2023

Wages and salaries		(10,003	)		(8,463	)
Social charges on free shares and stock option grants		39			(47	)
Non-cash stock-based compensation expense		(1,454	)		(1,186	)
Personnel expenses		(11,419	)		(9,696	)
Purchases and external expenses		(9,847	)		(8,352	)
Other		(4,364	)		(4,097	)
Total research and development expenses		(25,630	)		(22,144	)


	For the three-month period ended June 30,
Selling, general and administrative expenses	2022 *			2023

Wages and salaries		(1,593	)		(1,480	)
Social charges on free shares and stock option grants		7			(7	)
Non-cash stock-based compensation expense		(557	)		(460	)
Personnel expenses		(2,142	)		(1,947	)
Purchases and external expenses		(2,019	)		(1,284	)
Other		(669	)		(719	)
Total selling, general and administrative expenses		(4,830	)		(3,950	)


	For the three-month period ended June 30,
Personnel expenses	2022 *			2023

Wages and salaries		(11,596	)		(9,943	)
Social charges on free shares and stock option grants		46			(54	)
Non-cash stock-based compensation expense		(2,011	)		(1,646	)
Total personnel expenses		(13,561	)		(11,643	)


	For the three-month period ended June 30,
	2022 *		2023
Other operating income (expenses)		753		490

* These amounts reflect adjustments made in connection with the presentation of the discontinued operation (Note 5)

The decrease in total operating expenses of $4.4 million from the three-month period ended June 30, 2022 to the three-month period ended June 30, 2023 resulted primarily from (i) a decrease of $2.5 million in purchases, external expenses and other, due to continuing internalization of manufacturing and quality control activities (ii) a decrease of $1.7 million in wages due to headcount reduction, (iii) a decrease of $0.4 million in non-cash stock based compensation expense, (iv) a decrease of $0.3 million in cost of revenues due to the diminution of milestones recognition partially offset by (i) a $0.1 million increase in social charges on stock option grants expenses and (ii) a decrease of $0.3 million in other operating income.

4.3 Reportable segments

Accounting policies

Reportable segments are identified as components of the Group that have discrete financial information available for evaluation by the Chief Operating Decision Maker (“CODM”), for purposes of performance assessment and resource allocation.

For the six-month period ended June 30, 2023, Cellectis’ CODM is composed of:

•

The Chief Executive Officer;

•

The Executive Vice President CMC and Manufacturing;

•

The Senior Vice President of US Manufacturing;

•

The Chief Scientific Officer;

•

The Chief Financial Officer

•

The General Counsel;

•

The Chief Business Officer;

•

The Chief Regulatory & Pharmaceutical Compliance Officer;

•

The Chief Medical Officer; and

•

The Chief Human Resources Officer.

Until May 31, 2023, we viewed our operations and manage our business in two operating and reportable segments that are engaged in the following activities:

•

Therapeutics: This segment is focused on the development of (i) gene-edited allogeneic Chimeric Antigen Receptor T-cells product candidates (UCART) in the field of immuno-oncology (UCART) and (ii) gene-edited hematopoetic stem and progenitor cells (HSPC) product candidates in other therapeutic indications. These approaches are based on our core proprietary technologies. All these activities are supported by Cellectis S.A., Cellectis, Inc. and Cellectis Biologics, Inc. The operations of Cellectis S.A., the parent company, are presented entirely in the Therapeutics segment which also comprises research and development, management and support functions.

•

Plants: This segment is focused on using Calyxt’s proprietary PlantSpringTM technology platform to engineer plant metabolism to produce innovative, high-value, and sustainable materials and products for use in helping customers meet their sustainability targets and financial goals. Calyxt’s diversified product offerings will primarily be delivered through its proprietary BioFactory™ production system. It corresponds to the activity of Calyxt. As of May 31, 2023, immediately prior the consummation of the Merger we owned a 48.0% equity interest in Calyxt. This segment is only related to assets held for sale until May 31, 2023. This segment is presented as assets held for sale as of December 31, 2022 and discontinued operations for the six-month period ended June 30, 2023 and 2022. All tables referring to the six-month period ended June 30, 2023 present Calyxt’s results over a five-month period from January 1, 2023 to May 31, 2023.

As from June 1, 2023 and the deconsolidation of Calyxt, the Therapeutics segment is the Group’s only reportable segment.

Following the consummation of the Merger, we view our operations and manage our business in a single operating and reportable segment corresponding to the Therapeutics segment.

There are inter-segment transactions between the two reportable segments, including allocation of corporate general and administrative expenses by Cellectis S.A. and allocation of research and development expenses to the reportable segments.

The intersegment revenues represent the transactions between segments. Intra-segment transactions are eliminated within a segment’s results and intersegment transactions are eliminated in consolidation as well as in key performance indicators by reportable segment.

Information related to each reportable segment is set out below. Segment revenues and other income, research and development expenses, selling, general and administrative expenses, and cost of revenue and other operating income and expenses, and adjusted net income (loss) attributable to shareholders of Cellectis (which does not include non-cash stock-based compensation expense) are used by the CODM for purposes of making decisions about allocating resources to the segments and assessing their performance. The CODM does not review any asset or liability information by segment or by region.

Adjusted net income (loss) attributable to shareholders of Cellectis S.A. is not a measure calculated in accordance with IFRS. Because adjusted net income (loss) attributable to shareholders of Cellectis excludes non-cash stock-based compensation expense—a non-cash expense, our management believes that this financial measure, when considered together with our IFRS financial statements, can enhance an overall understanding of Cellectis’ financial performance. Moreover, our management views the Company’s operations, and manages its business, based, in part, on this financial measure.

Net income (loss) by segment includes the impact of the transactions between segments while the intra-segment operations are eliminated.

Details of key performance indicators by reportable segment for the six months period ended June 30, 2022 and 2023.


	For the six-month period ended June 30, 2022									For the six-month period ended June 30, 2023
$ in thousands	Plants (discontinued operations)			Therapeutics			Total reportable segments			Plants (discontinued operations)			Therapeutics			Total reportable segments

External revenues		73			2,972			3,045			43			317			360
External other income		—			3,551			3,551			—			5,242			5,242
External revenues and other income		73			6,523			6,596			43			5,560			5,602
Cost of revenue		(0	)		(714	)		(714	)		(63	)		(389	)		(451	)
Research and development expenses		(6,297	)		(52,231	)		(58,527	)		(3,487	)		(43,225	)		(46,712	)
Selling, general and administrative expenses		(6,801	)		(10,893	)		(17,695	)		(2,313	)		(8,914	)		(11,227	)
Other operating income and expenses		242			774			1,016			(1,251	)		(83	)		(1,334	)
Total operating expenses		(12,856	)		(63,064	)		(75,920	)		(7,113	)		(52,612	)		(59,725	)
Operating income (loss) before tax		(12,783	)		(56,541	)		(69,324	)		(7,070	)		(47,053	)		(54,123	)
Net financial gain (loss)		5,900			9,213			15,113			(3,307	)		11,580			8,273
Income tax		—			—			—			—			(258	)		(258	)
Net income (loss) from discontinued operations		(6,883	)					(6,883	)		(10,377	)					(10,377	)
Net income (loss)		(6,883	)		(47,328	)		(54,211	)		(10,377	)		(35,731	)		(46,108	)
Non-controlling interests		3,352			—			3,352			5,393			—			5,393
Net income (loss) attributable to shareholders of Cellectis		(3,531	)		(47,328	)		(50,858	)		(4,984	)		(35,731	)		(40,715	)
R&D non-cash stock-based expense attributable to shareholder of Cellectis		216			3,134			3,349			188			1,900			2,088
SG&A non-cash stock-based expense attributable to shareholder of Cellectis		789			1,193			1,982			599			1,366			1,965
Adjustment of share-based compensation attributable to shareholders of Cellectis		1,005			4,327			5,331			788			3,265			4,053
Adjusted net income (loss) attributable to shareholders of Cellectis		(2,526	)		(43,001	)		(45,527	)		(4,196	)		(32,465	)		(36,662	)
Depreciation and amortization		(1,316	)		(9,434	)		(10,749	)		(7	)		(8,875	)		(8,882	)
Additions to tangible and intangible assets		671			1,452			2,123			21			536			556

Details of key performance indicators by reportable segment for the three months period ended June, 30, 2022 and 2023.


	For the three-month period ended June 30, 2022									For the three-month period ended June 30, 2023
$ in thousands	Plants (discontinued operations)			Therapeutics			Total reportable segments			Plants (discontinued operations)			Therapeutics			Total reportable segments

External revenues		42			1,307			1,348			1			178			179
External other income		—			1,416			1,416			—			1,823			1,823
External revenues and other income		42			2,723			2,765			1			2,001			2,002
Cost of revenue		0			(329	)		(329	)		(63	)		(55	)		(118	)
Research and development expenses		(3,419	)		(25,630	)		(29,048	)		(1,322	)		(22,144	)		(23,467	)
Selling, general and administrative expenses		(3,585	)		(4,830	)		(8,415	)		(976	)		(3,950	)		(4,927	)
Other operating income and expenses		198			753			951			(1,074	)		490			(584	)
Total operating expenses		(6,806	)		(30,036	)		(36,842	)		(3,435	)		(25,660	)		(29,095	)
Operating income (loss) before tax		(6,764	)		(27,313	)		(34,077	)		(3,434	)		(23,659	)		(27,093	)
Financial gain (loss)		6,322			8,301			14,623			(2,213	)		15,982			13,769
Income tax		—			—			—			—			(258	)		(258	)
Net income (loss) from discontinued operations		(442	)					(442	)		(5,647	)					(5,647	)
Net income (loss)		(442	)		(19,012	)		(19,454	)		(5,647	)		(7,935	)		(13,583	)
Non controlling interests		506			—			506			(2,935	)		—			(2,935	)
Net income (loss) attributable to shareholders of Cellectis		64			(19,012	)		(18,946	)		(2,712	)		(7,935	)		(10,648	)
R&D non-cash stock-based expense attributable to shareholder of Cellectis		226			1,454			1,681			103			797			900
SG&A non-cash stock-based expense attributable to shareholder of Cellectis		447			557			1,003			326			849			1,174
Adjustment of share-based compensation attributable to shareholders of Cellectis		673			2,011			2,684			428			1,646			2,074
Adjusted net income (loss) attributable to shareholders of Cellectis		737			(17,001	)		(16,264	)		(2,284	)		(6,289	)		(8,573	)
Depreciation and amortization		(608	)		(4,500	)		(5,108	)		(12	)		(4,419	)		(4,431	)
Additions to tangible and intangible assets		308			870			1,178			21			311			332

4.4 Financial income and expenses

4.4.1 For the six-month period ended June 30


	For the six-month period ended June 30,
Financial income and expenses	2022			2023

Income from cash, cash equivalents and financial assets		311			1,441
Foreign exchange gains		8,310			9,248
Gain on fair value measurment		3,642			593
Other financial income		-			21,759
Financial income		12,263			33,041
Interest on financial liabilities		(176	)		(690	)
Foreign exchange losses		(878	)		(2,278	)
Loss on fair value measurment		(247	)		(16,931	)
Interest on lease liabilities		(1,748	)		(1,561	)
Other financial expenses		—			(1	)
Financial expenses		(3,050	)		(21,461	)
Net financial gain (loss)		9,213			11,580

The increase in financial income of $20.8 million between the six-month periods ended June 30, 2022 and 2023 was mainly attributable to the profit from Calyxt’s deconsolidation of $21.8 million, an increase in gain from our financial investments of

$1.1 million, an increase in the foreign exchange gain of $0.9 million (from a $8.3 million gain in 2022 to a $9.2 million gain in 2023, of which $8.0 million are reclassified from OCIs pursuant to Calyxt’s deconsolidation), and a $0.4 million gain on change in fair value of the EIB warrants, partially offset by a $3.6 million decrease in gain on fair value of Cytovia’s note receivable (in addition to the $6.8 million loss recognized in financial expenses in 2023).

The increase in financial expenses of $18.4 million between the six-month periods ended June 30, 2022 and 2023 is mainly attributable to the loss in fair value on our retained investment in Calyxt since deconsolidation for $10.2 million, a $6.8 million decrease in the fair value of Cytovia’s note receivable, a $1.4 million increase in foreign exchange loss (from a $0.9 million loss in 2022 to a $2.3 million loss in 2023) and an increase of loan interest for $0.4 million related to the EIB loan.

4.4.2 For the three-month period ended June 30


	For the three-month period ended June 30,
Financial income and expenses	2022			2023

Income from cash, cash equivalents and financial assets		205			761
Foreign exchange gains		6,146			9,216
Gain on fair value measurment		3,642			531
Other financial income		—			21,759
Financial income		9,992			32,266
Interest on financial liabilities		(111	)		(573	)
Foreign exchange losses		(592	)		(1,289	)
Loss on fair value measurment		(125	)		(13,648	)
Interest on lease liabilities		(863	)		(774	)
Other financial expenses		(0	)		(0	)
Financial expenses		(1,691	)		(16,284	)
Net financial gain (loss)		8,301			15,982

The increase in financial income of $22.3 million between the three-month periods ended June 30, 2022 and 2023 was mainly attributable to the profit from Calyxt’s deconsolidation of $21.8 million, an increase in gain from our financial investments of $0.6 million, an increase in the foreign exchange gain of $3.1 million (from a $6.1 million gain in 2022 to a $9.2 million gain in 2023, of which $8.0 million are reclassified from OCIs pursuant to Calyxt’s deconsolidation), and a $0.4 million gain on change in fair value of the EIB warrants, partially offset by a $3.6 million decrease in gain on fair value of Cytovia’s note receivable (in addition to the $3.5 million loss recognized in financial expenses in 2023).

The increase in financial expenses of $14.6 million between the six-month periods ended June 30, 2022 and 2023 is mainly attributable to the loss in fair value on our retained investment in Calyxt since deconsolidation for $10.2 million, a $3.5 million decrease in the fair value of Cytovia’s note receivable, a $0.7 million increase in foreign exchange loss (from a $0.6 million loss in 2022 to a $1.3 million loss in 2023) and an increase of loan interest for $0.4 million related to the EIB loan.

Share capital and premium related to the share capitals - Schedule of Classes of Share Capital (Detail) - USD ($)
$ / shares in Units, $ in Thousands

3 Months Ended

6 Months Ended

Dec. 31, 2022

Jun. 30, 2023

Jun. 30, 2022

Disclosure of classes of share capital [line items]

Beginning balance

$ 125,941

$ 236,474

Balance at beginning, Number of shares

45,675,968

45,484,310

Capital increase by issuance of common shares

9,907,800

Exercise of share warrants, employee warrants and stock options

26,500

Balance at end, Number of shares

^[1]

$ (257)

Balance at end of year

$ 125,941

$ 96,558

$ 180,522

45,675,968

55,583,768

45,510,810

Nominal value

$ 0.05

Share Capital Ordinary Shares [member]

Disclosure of classes of share capital [line items]

Beginning balance

$ 2,955

$ 2,945

Capital increase of Cellectis

536

Exercise of share warrants, employee warrants and stock options

Balance at end of year

$ 2,955

3,491

2,946

Disclosure of classes of share capital [line items]

Beginning balance

583,122

934,696

Capital increase of Cellectis

24,482

Transaction costs related to Cellectis' capital increase

4,053

5,331

(1,455)

(133,976)

^[1]

(372,744)

Balance at end of year

$ 583,122

$ 476,224

$ 567,284

[1]

During the annual shareholders meeting of June 27, 2023, the shareholders, in accordance with French Law, approved the absorption of $134.0 million of retained earnings into share premium. This transaction has no impact on the total equity, comprehensive income (loss), assets (including cash) nor liabilities.

Scope of Consolidation and Non-Consolidated Entities - Additional Information (Detail)						1 Months Ended	6 Months Ended	12 Months Ended
	Jun. 01, 2023	May 31, 2023 shares	May 17, 2023 shares	Dec. 29, 2022 Product	Nov. 23, 2022	Jun. 30, 2023	Jun. 30, 2023	Dec. 31, 2022
Disclosure of Information about Consolidated and Non-consolidated Structured Entities [Line Items]
Ownership interest in subsidiary						100.00%
Percentage of shareholding diluted of merged entity					2.40%
Cibus Global [Member]
Disclosure of Information about Consolidated and Non-consolidated Structured Entities [Line Items]
Ownership interest in subsidiary	2.90%
Cibus Global [Member] \| Class A Common Stock [Member]
Disclosure of Information about Consolidated and Non-consolidated Structured Entities [Line Items]
Number of shares issued		16,527,484
Cellectis, Inc. [member]
Disclosure of Information about Consolidated and Non-consolidated Structured Entities [Line Items]
Ownership interest in subsidiary							100.00%
Cellectis, Inc. [member] \| Cellectis Biologics, Inc. [Member]
Disclosure of Information about Consolidated and Non-consolidated Structured Entities [Line Items]
Ownership interest in subsidiary							100.00%
Calyxt [member]
Disclosure of Information about Consolidated and Non-consolidated Structured Entities [Line Items]
Ownership interest in subsidiary		48.00%
Primera Therapeutics, Inc. [Member]
Disclosure of Information about Consolidated and Non-consolidated Structured Entities [Line Items]
Name of associate				Primera Therapeutics, Inc.
Maximum number of exclusive license for product candidates \| Product				5
Number of common stock received			234,570
Ownership interest in associate			19.00%				17.00%
Voting rights held in associate			19.00%				17.00%
Calyxt ATM Program [Member] \| Cellectis, Inc. [member]
Disclosure of Information about Consolidated and Non-consolidated Structured Entities [Line Items]
Non-controlling shareholders interest		52.00%						50.90%

Accounting principles	6 Months Ended
Accounting principles	Jun. 30, 2023
Text block1 [abstract]
Accounting principles	Note 2. Accounting principles 2.1 Basis for preparation The Interim Consolidated Financial Statements of Cellectis as of, and for the six-month period ended, June 30, 2023 were approved by our Board of Directors on August 3, 2023. The Interim Consolidated Financial Statements are presented in thousands of U.S. dollars. See Note 2.2. The Interim Consolidated Financial Statements as of, and for the six-month period ended June 30, 2023 have been prepared in accordance with International Accounting Standard (“IAS”) 34 Interim Financial Reporting, as issued by the International Accounting Standards Board (“IASB”). The Interim Consolidated Financial Statements as of and for the six-month period ended June 30, 2023 have been prepared using the same accounting policies and methods as those applied for the year ended December 31, 2022, except as described below related to the new or amended accounting standards applied. IFRS include International Financial Reporting Standards (“IFRS”), International Accounting Standards (“the IAS”), as well as the interpretations issued by the Standards Interpretation Committee (“the SIC”), and the International Financial Reporting Interpretations Committee (“IFRIC”). Application of new or amended accounting standards or new amendments The following pronouncements and related amendments have been adopted by us from January 1, 2023 but had no significant impact on the Interim Consolidated Financial Statements: • IFRS 17 Insurance Contracts (including Amendments to IFRS 17 issued in June 2020 and Amendment to IFRS 17 - Initial Application of IFRS 17 and IFRS 9 – Comparative Information issued in December 2021) (issued in May 2017 and Effective for the accounting periods as of January 1, 2023) • Amendments to IAS 1 – Classification of Liabilities as Current or Non-current (issued in July 2020 and Effective for the accounting periods as of January 1, 2023) • Amendments to IAS 8 – Definition of Accounting Estimates (issued on 12 February 2021 and Effective for the accounting periods as of January 1, 2023) • Amendments to IAS 1 and IFRS Practice Statement 2 –Disclosure of Accounting Policies (issued in March 2021 and Effective for the accounting periods as of January 1, 2023) • Amendments to IAS 12 – Income Taxes: Deferred Tax related to Assets and Liabilities arising from a Single Transaction (issued in May 2021 and Effective for the accounting periods as of January 1, 2023) Accounting standards, interpretations and amendments issued but not yet effective The following pronouncements and related amendments are applicable for first quarter accounting periods beginning after January 1, 2024, or later, as specified below. The Group has not early adopted any of these pronouncements and amendments. We are currently evaluating if the adoption of these pronouncements and amendments will have a material impact on our results of operations, financial position, or cash flows: • Amendments to IAS 1 regarding the classification of liabilities (issued in January 2020 and Effective for the accounting periods as of January 1, 2024) • Amendments to IAS 1 regarding the classification of debt with covenants (issued in October 2022 and Effective for the accounting periods as of January 1, 2024) • Amendment to IFRS 16 to “clarify how a seller-lessee subsequently measures sale and leaseback transactions” (issued in September 2022 and Effective for the accounting periods as of January 1, 2024) Going concern The consolidated financial statements were prepared on a going concern basis. With cash and cash equivalents of $84,386 thousand as of June 30, 2023, the Company believes it has sufficient resources to continue operating for at least twelve months following the consolidated financial statements’ publication. Our assessment of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves uncertainties, and actual results could vary as a result of a number of factors. We have based this estimate on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect or chose to revise our strategy to extend our cash runway. To the extend that the company has built its cash forecast to support its ability to continue as a going concern, management considers to have the ability to extend the cash runway even further by prioritizing some clinical programs, save SG&A expenses, raising funds on the markets. 2.2 Currency of the financial statements The Interim Consolidated Financial Statements are presented in U.S. dollars, which differs from the functional currency of Cellectis, which is the euro. We believe that this presentation enhances the comparability with peers, which primarily present their financial statements in U.S. dollars. All financial information (unless indicated otherwise) is presented in thousands of U.S. dollars. The statements of financial position of consolidated entities having a functional currency different from the U.S. dollar are translated into U.S. dollars at the closing exchange rate (spot exchange rate at the statement of financial position date) and the statements of operations, statements of comprehensive income (loss) and statements of cash flows of such consolidated entities are translated at the average period to date exchange rate. The resulting translation adjustments are included in equity under the caption “Accumulated other comprehensive income (loss)” in the Statements of Changes in Shareholders’ Equity. 2.3 Consolidated entities and non-controlling interests Accounting policy We control all the legal entities included in the consolidation. An investor controls an investee when the investor is exposed to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee. Control requires power, exposure to variability of returns and a linkage between the two. To have power, the investor needs to have existing rights that give it the current ability to direct the relevant activities that significantly affect the investee’s returns. In order to ascertain control, potential voting rights which are substantial are taken into consideration. Consolidation of a subsidiary begins when the Group obtains control over the subsidiary and ceases when the Group loses control of the subsidiary. All intra-Group assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated in full in the consolidation. Investments in associates Associates are entities in which the Group has significant influence in respect of financial and operating policy decisions, but not control. Significant influence is assessed through voting rights. Investments in associates are accounted for under the equity method and are initially recognized at cost. The consolidated financial statements include the Group’s share of the total comprehensive income of associates from the date when significant influence is obtained until the date it ceases. If the Group’s share of losses exceeds its equity interest, the carrying amount of investments consolidated under the equity method is reduced to zero and the Group ceases to recognize its share of future losses unless the Group has a legal or constructive obligation to bear a portion of future losses or to make payments on behalf of the associate.

Non-cash stock-based compensation - Additional Information (Detail) $ in Millions				1 Months Ended	6 Months Ended		12 Months Ended
	Jun. 26, 2023	May 04, 2023	Jan. 24, 2023 shares	Oct. 31, 2020	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2017
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period, years					4 years
Stock option expire, years					10 years
Performance Stock Unit [Member] \| Calyxt [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share based payment expense					$ 0.3	$ 0.3
Stock options [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period, years	4 years	4 years	4 years
Share-based compensation expense					$ 1.4	1.8
Number of equity instruments granted in share-based payment arrangement	55,690	358,100	1,417,321		1,835,411		828,549
Stock options [member] \| Calyxt [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation expense					$ 0.8	0.9
S A free shares [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period, years			3 years
Share-based compensation expense					$ 1.9	2.5
Vesting description					The free shares granted in 2018 and until 2021 are subject to at least one-year vesting and additional one-year vesting period for French residents and two-years vesting period for foreign residents. The vesting of free shares granted to executive officers of the Company in October 2020 are subject to performance conditions with a minimum vesting of a 3-year period.
Number of other equity instruments granted in share-based payment arrangement \| shares			340,750
Number of equity instruments granted in share-based payment arrangement					342,900		354,770
S A free shares [member] \| French employees [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period, years					1 year
S A free shares [member] \| Foreign citizens [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period, years					2 years
S A free shares [member] \| Executive Officers [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period, years				3 years
S A free shares [member] \| Executive Officers [Member] \| Granted in Two Thousand And Twenty One [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period, years								3 years
S A free shares [member] \| French Resident Employees [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period, years									2 years
Share Based Arrangement Additional Vesting Period					1 year
Additional holding period									2 years
S A free shares [member] \| Foreign Resident Employees [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period, years									4 years
S A free shares [member] \| Employees [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period, years								3 years
RSU Calyxt 2017 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share based payment expense					$ 0.5	0.7
Non Employee Warrants [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation expense					$ 0.0	$ 0.0

Intangible Assets - Details Information About Intangible Assets (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	May 31, 2023
Disclosure of detailed information about intangible assets [line items]
Beginning balance		$ 718
Ending balance	$ 695

Information concerning the Group's Consolidated Operations (Tables)

6 Months Ended

Jun. 30, 2023